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Summary 
 
The future vision in the battle against malaria goes beyond controlling the 
disease. Envisioned is the world-wide eradication of malaria. A substantial 
contribution to reach this goal is the development of an effective vaccine. Today’s 
most advanced and most effective malaria vaccine, RTS,S/AS01, showed 
efficacy of 30 to 66% against all clinical episodes. There is a great need to 
increase efficacy by the next generation malaria vaccines. A strategy for 
increasing RTS,S efficacy could be to combine it with an effective blood stage 
vaccine. The disappointing outcomes of clinical trials conducted for most current 
blood stage vaccines demands the identification of novel promising candidates. 
 
Under persistent exposure individuals develop immunity that protects against 
clinical disease but not parasitemia. This natural acquired immunity develops 
slowly and is reached in adolescence. In contrast, immunity against severe 
disease develops already after few infections. The mechanisms that underlie 
naturally acquired immunity or severe disease immunity remain poorly 
understood. Antibodies were demonstrated to play a critical role for controlling 
blood stage infection. It remains unclear which proteins elicit the production of 
protective antibodies and through which antibody effector function protection is 
provided. The relevance of antibodies in blood stage protection has the 
consequence that the immunogen correctly mimic the three-dimensional 
structure of the native protein. This PhD thesis has its major focus on 
immunogens that adopt a stable tertiary structure in aqueous environment.  
 
The availability of the P. falciparum genome sequences, transcriptome and 
proteome data has opened the avenue for the identification of novel targets for 
vaccine development. However, blood stage vaccine development has focused 
on only a few candidates. Previously our collaborators in this project have 
identified promising candidates by genome-wide screening for alpha-helical 
coiled coil domains in proteins expressed in the erythrocytic parasite stages. The 
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segments with high probability score for coiled coil formation where selected. The 
166 coiled coil segments derived from 131 proteins representing 4% of the blood 
stage proteome. 95 coiled coil fragments of a length of 30-40 amino acids were 
synthesized and analyzed systematically in a pre-clinical evaluation pathway. 
 
The aim of this thesis was to fill the gaps in the preclinical evaluation pathway of 
novel synthetic peptide vaccine candidates.  
 
The extensive polymorphism found in most parasite antigens represents a major 
obstacle for the development of efficacious blood stage vaccines. The genetic 
diversity of the identified coiled coil protein segments was studied in great detail. 
We found that coiled coil segments are well conserved, 82% of all selected 166 
segments showed complete sequence conservation. Polymorphism was found 
predominantly in segments containing almost perfect tandem repeats. Based on 
these findings an optimized bioinformatic selection strategy was formulated 
proposing to exclude coiled coil segments consisting of almost perfect tandem 
repeats. 
 
The availability of basic knowledge about vaccine candidates is a prerequisite for 
vaccine development and is essential to attract further funding for continued 
clinical development. A detailed cell biological characterization was undertaken 
for the most promising candidate, PFF0165c (newly termed Trophozoite exported 
protein 1 (Tex1)) Transcript and protein levels were analyzed throughout the 
intra-erytrocytic development cycle. Tex1 transcripts were found up-regulated in 
the early trophozoite stage. This was supported by Tex1 protein levels. Tex1 
abundance persisted until parasite egress. Immunofluorescence experiments 
revealed that Tex1 is exported and associates to parasite-derived structures, 
termed Maurer’s clefts. Before parasite egress Tex1 resides in close proximity to 
the red blood cell membrane. In the search of sequence motifs responsible for 
Tex1 export we found that the actual translational start site is positioned 43 
amino acids upstream of the start site previously predicted. The additional 43 
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amino acids function as signal peptide, directing the protein into the classical 
secretory pathway.  
 
This thesis contributed to the immunological characterization of the intrinsically 
unstructured region (P27A) of Tex1. P27A was evaluated for vaccine potential 
and met the principal requirements to be downselected for a phase 1 trial. P27A 
was recognized by a majority of naturally exposed individuals, highly 
immunogenic, highly conserved and P27A-specific human and mouse sera were 
effective in in vitro parasite killing by Antibody-dependent cellular inhibition 
assay. High P27A-specifc antibody titers were found to positively correlate with 
protection. Clinical grade P27A peptide is currently produced.  
 
In order to validate synthetic peptides as antigens the recognition by sera of 
adults from endemic region was compared to the recognition of the antigen 
recombinant expressed in E. coli. Comparable recognition of both types of 
antigens was observed. 
 
This thesis provides evidence that the approach initiated by our collaborators is 
invaluable. This strategy, if proven successful in clinical trials, could be applied 
for vaccine development against many other pathogens from which genome data 
is available.  
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Abbreviations 
 
RBC   red blood cell 
iRBC   infected red blood cell 
uRBC   uninfected red blood cell 
PfEMP1  Plasmodium falciparum erythrocyte protein 1 
Abs   antibodies 
IDC   intra-erythrocytic development cycle 
PE   pre-erythrocytic stage 
RAS   radiation-attenuated sporozoites 
CSP   circumsporozoite protein 
PV   parasitophorous vacuole 
PVM   parasitophorous vacuole membrane 
MC   Maurer’s clefts 
PEXEL  Plasmodium export element 
VTS   vacuole transport signal 
ER   endoplasmic reticulum 
RAS   radiation-attenuated sporozoites 
MSP1, 2, 3   merozoite surface protein 1, 2, 3 
AMA1   apical membrane antigen 1 
EBA175, 140, 181 erythrocyte binding antigen 175, 140, 181 
SERA   serine-rich antigen 
EXP1   exported protein 1 
GLURP  glutamate-rich protein 
NK   natural killer cell 
DC   dendritic cell 
IFNγ   interferon-gamma 
CC   alpha-helical coiled-coil 
ADCI   antibody dependent cellular inhibition 
Tex1   Trophozoite exported protein 1 (PFF0165c) 
IUR   intrinsically unstructured region 
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P27A   intrinsically unstructured region of Tex1 
P27   alpha-helical coiled-coil motif of Tex1 
P90   alpha-helical coiled-coil motif of PFD0520c 
ELISA   Enzyme -linked immunosorbent assay 
recPFD0520c PFD0520c recombinantly expressed in E. coli 
CD   Circular dichroism 
MAHRP1  membrane-associated histidine-rich protein-1 
MAHRP2  membrane-associated histidine-rich protein-2 
SBP1   skeleton-binding protein-1 
Rex1, 2  Ring exported protein 1, 2 
KAHRP  knob-associated histidine-rich protein 
PNEPs  PEXEL-negative exported proteins 
MS   mass spectrometry 
MHC   major histocompatibility complex molecules 
 
 
CHAPTER1: INTRODUCTION 
 11 
Chapter 1: Introduction  
 
1.1 Malaria disease 
Malaria is caused by the parasitic protozoan Plasmodium.  P. falciparum is 
responsible for the most common and serious form of the disease. Approximately 
one-third of the world's population is at risk of malaria infection. Per year, malaria 
is estimated to affect 300-500 million individuals and lead to 1-3 million deaths, 
the majority being young children [1]. There is a striking correlation between 
malaria and poverty, and malaria-endemic countries have lower rates of 
economic growth [2]. Sub-Saharan Africa has the largest burden of malaria and 
accounts for 70% of all malaria cases worldwide. 
 
The pathogenesis of human P. falciparum infection is a complex interplay of 
parasite-induced red blood cell (RBC) alteration, microcirculatory abnormalities, 
accompanied by local and systemic immune reactions resulting in multiple 
clinical forms of variable severity [3]. Severe malaria includes cerebral malaria 
and/or severe malarial anemia combined with complications of hypoglycemia 
and/or acidosis.  
 
Cerebral malaria stems from the ability of later stage (trophozoite or schizont) 
infected RBCs (iRBC) to sequester in narrow blood vessels thus preventing 
clearance from the spleen [4]. Sequestration is mediated by adherence to 
endothelial cells, uninfected RBCs, platelets and other blood cells [4]. A 
prominent parasite molecule involved in cytoadherence is the P. falciparum 
erythrocyte membrane protein 1 (PfEMP1). Due to its role in RBC sequestration, 
PfEMP1 is regarded as a major virulence factor. PfEMP1 is encoded by a multi-
gene family consisting of 60 var genes that are expressed in a mutually exclusive 
manner in that only one variant is expressed at a single time point per parasite. 
The generation of antibodies against frequent PfEMP1 variants has been shown 
to contribute to protection against severe disease [5,6]. 
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Severe malarial anemia results from massive RBC loss and/or impaired 
erythropoiesis [7]. Rupture of iRBC upon parasite egress as well as destruction 
of uninfected RBCs (uRBC) contribute to dramatically diminished cell counts. 
uRBCs have been shown to be modified by parasite molecules released during 
invasion. These modifications lead to spleen-mediated clearance, phagocytosis 
or complement-mediated lysis in the presence of specific antibodies [8,9,10]. 
 
The mechanisms underlying hypoglycemia and acidosis in malaria are not fully 
understood. These are a common complications of severe malaria frequently 
seen in children in combination with cerebral malaria [11,12]. 
 
1.2 Life cycle 
P. falciparum undergoes a complex life cycle during which it goes through 
morphologically distinct stages. Infection of the human host occurs by the bite of 
a female Anopheles mosquito. Plasmodium sporozoites are harbored in the 
salivary glands and transferred during the blood meal into the human host. The 
sporozoites immediately find their way into the liver via the blood stream and 
invade hepatocytes. Within the liver cells, the parasite multiplies asexually to 
produce 10’000 to 30’000 merozoites which are capable of invading RBCs. All 
clinical symptoms are associated exclusively with the asexual multiplication in 
RBCs (completed every 48 hours). During the intra-erythrocytic development 
cycle (IDC) some merozoites enter a sexual differentiation program and develop 
into gametocytes. The mature gametocytes are eventually taken up by the 
mosquito during a blood meal. The sudden change in environmental conditions 
triggers male gametocytes to develop into motile microgametes and female 
gametocytes into round gametes [13]. Fusion of a male microgamete with a 
female gamete gives rise to a zygote that initiates meiosis and further develops 
into a motile ookinete. The ookinete traverses the mid-gut epithelium and 
develops into an oocyst. Sporozoites develop within the oocysts. Upon release 
sporozoites migrate to the salivary gland of the mosquito. 
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1.3 P. falciparum intra-erythrocytic development cycle 
The IDC is responsible for all the clinical symptoms associated with malaria 
disease. Up to 30’000 merozoites are formed per infected hepatocyte. These 
merozoites are released in the blood stream and are capable of invading RBCs. 
Plasmodium parasites belong to the phylum Apicomplexa. All apicomplexan 
parasites share various features, including the presence of a specialized apical 
complex, which is central to the invasion process. During the IDC the parasites 
develop from the ring stage (hours 0 to 22 post invasion) to the trophozoite 
(hours 22 to 36 post invasion) to the schizont stage (hours 36 to 48 post 
invasion). During the schizont stage the parasite develops into 16-32 infective 
merozoites that are released upon RBC rupture. 
  
1.3.1 Merozoite invasion 
The whole process of merozoite invasion occurs very rapidly within 10-60 
seconds [14,15]. Since the RBC is non-endocytic, merozoite invasion is an 
entirely active process. After the initial reversible interaction with the erythrocyte, 
the merozoite re-orients to bring its apical end into direct contact with the 
erythrocyte plasma membrane. To enter the cell, an irreversible interaction, the 
“tight junction”, is formed between the parasite and the host membrane. The tight 
junction then migrates towards the posterior end of the merozoite. As the 
parasite pushes its way into the host cell, it creates a parasitophorous vacuole 
(PV) to seal itself off from the host-cell cytoplasm and form an environment 
hospitable for its development.  
 
1.3.2 Remodeling of the infected erythrocyte 
After parasite invasion, fundamental structural and morphological changes occur 
in the iRBC. These changes include the generation of an elaborate membrane 
system in the RBC cytosol  known as the tubulovesicular network, which 
emanates from the parasitophorous vacuole membrane (PVM) [16], and 
compartments known as Maurer’s clefts (MC) [17,18,19]. The parasite modifies 
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the RBC surface leading to knob-like protrusions which anchor proteins involved 
in cytoadherence [20].  
 
The MC are flat and elongated membrane-bound cisterna with an electron-dense 
coat and electron-lucent lumen. MC are intermediate compartments for the 
transport of many parasite-derived proteins to various destinations within the 
RBC cytosol, cytoskeleton or membrane. These exported proteins function in the 
generation of new permeation pathways for nutrient uptake or act as virulence 
factors. The major virulence factor, the erythrocyte membrane protein-1 
(PfEMP1), is trafficked via the MC to the RBC surface [21]. PfEMP1 localizes to 
the knobs and mediates adherence of the trophozoite and schizont infected 
RBCs to the host endothelium [22]. 
 
Recently, novel parasite-derived structures in the RBC cytosol have been 
identified. In close proximity to the MC, electron-dense tubular structures - so 
called “tethers” - were identified that were shown to connect the MC to the RBC 
membrane [16] [23].Vesicle-like structures of various sizes have been observed 
in the RBC cytosol [19,24,25,26,27].   
 
1.3.3 Protein export in P. falciparum 
A large number of parasite proteins are involved in the remodeling of the host 
cell. These proteins are exported beyond the plasma membrane of the parasite, 
across the PVM into the RBC cytosol, to the RBC membrane and beyond. In 
addition to cytoadherence and immune evasion, many exported proteins are 
involved in nutrient uptake and solvent exchange and therefore are crucial for 
parasite survival and development [4,28]. 
 
The Plasmodium export element sequence (PEXEL), or vacuole transport signal 
[29,30], located downstream of the hydrophobic N-terminal signal sequence 
functions as a signal for translocation across the PVM. Recently it was shown 
that the PEXEL motif is cleaved by a novel endoplasmic reticulum (ER) 
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peptidase, followed by acetylation [31,32,33]. The new N-terminus is thought to 
be recognized by a specific transporter located in the PVM [34]. There are 
several exported proteins that lack a PEXEL motif and/or a classical N-terminal 
signal sequence [23,35,36,37,38,39], suggesting the existence of an alternative 
translocation mechanism across the PVM. 
 
1.4 Malaria vaccine development 
Intervention strategies to fight against malaria include drug treatment of infected 
individuals, preventive drug treatment of populations at high risk of infection as 
well as insecticide-treated bed nets and indoor insecticide spraying for mosquito 
control. However, the spread of drug-resistant parasites and insecticide-resistant 
vectors is increasingly reducing the success of these interventions. Vaccination 
provides one of history’s most cost effective public-health tools. The development 
of a malaria vaccine has been identified as a key component in an integrated 
approach to malaria control and an important step toward sustainable elimination 
of malaria.  
 
An ideal malaria vaccine should be safe, cheap, easy to manufacture, easy to 
administer and confer long-lived immunity. The life cycle of Plasmodium 
parasites is highly complex, involving several developmental stages in both the 
insect (Anopheles species) and human host. Vaccine development strategies 
aim at inducing immunity against all stages of the life cycle. 
 
1.4.1 Vaccine development against the pre-erythrocytic stage 
Vaccines against the pre-erythrocytic stage (PE) target sporozoites transmitted 
by Anopheles mosquitoes as well as the liver stage of the parasite. It is well 
established that immunization with radiation-attenuated sporozoites (RAS) 
induces sterile protective immunity against malaria infection in humans [40,41] 
and rodents [42]. Gamma irradiation attenuated the parasite such that it could 
invade the host hepatocyte but failed to differentiate into erythrocytic stages [43]. 
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The fact that immunization with dead sporozoites did not confer protection 
[42,44] indicated that live sporozoites in the skin, infection of hepatocytes and the 
development to liver stages are crucial for inducing sterile protective immunity. 
The major obstacle for PE vaccine development is that the vaccine must provide 
100% protection. The development of one single liver stage parasite into 
merozoites entering the IDC would result in a blood stage infection. The 
development of RAS for vaccine development remains difficult. The safety and 
efficacy of RAS is dependent on a precise irradiation dose; too little irradiation 
allows the parasite to complete liver stage development and causes blood stage 
infection, too much irradiation inactivates the sporozoites and inactivated 
sporozoites do not induce significant protection [45]. The development of RAS for 
vaccine development meets great technical challenges and comprises many 
manufacturing-related safety risks. In addition to the correct irradiation dose, the 
contact of the RAS with human blood and potential contamination with salivary 
gland proteins creates great safety concerns [46]. The disadvantages 
accompanying the development of whole organism vaccines call for the 
development of recombinantly produced or synthetic vaccines, ideally composed 
of several subunits.   
 
The currently most advanced subunit vaccine directed against PE is RTS,S. 
RTS,S is based on the hepatitis B surface antigen virus-like particle platform, 
genetically engineered to include the carboxy terminus of the P. falciparum 
circumsporozoite protein (CSP) [47] [48]; [49]; [50]; [51]. The RTS,S vaccine has 
demonstrated efficacy against both infection and clinical malaria in adults and 
children in different endemic settings (reviewed in Casares et al., 2010). In a 
phase IIb trial conducted in Mozambique, RTS,S formulation (RTS,S/AS02) 
resulted in 65% protection against infection in infants however protection 
persisted only 3 month and completely waned after a 6 month period [52]. RTS,S 
formulated as RTS,S/AS01 showed equal efficacy against infection in infants 
however protection was shown to pesists longer (60% for 10 month) [53]. A 
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multicenter, mutlicountry Phase III clinical trials of RTS,S/AS01 is currently 
ongoing.  
 
The mechanism by which protection of around 50% of volunteers is attained 
remains unknown. An only weak association between CSP-specific antibody titer 
and protection was observed [54]. Vaccine development demands the 
identification of predictive correlates of protection after vaccination [55,56,57]. 
For the phase IIa RTS,S trials conducted in adults, an up-regulation of genes 
involved in the immunoproteasome pathway was detected in protected 
individuals after vaccination, when compared to unprotected individuals [58]. 
Immuno-proteasomes are absolutely essential for generating ligands bound by 
major histocompatibility complex molecules (MHC). This indicates that adaptive 
immune responses are involved in RTS,S-induced protection.  
 
1.4.2 Vaccine development against the gametocyte stage 
Another malarial life cycle stage which vaccines target is the gametocyte stage 
(mosquito, gamete, or sexual stage). It has been shown that antibodies against 
gametocytes generated in the infected or immunized host can contribute to killing 
of the parasite once the mosquito has taken a blood meal and parasites have 
emerged from the host erythrocyte [59,60]. The approach to kill parasites within 
the vector through immune factors taken up with the blood meal can prevent 
development of infective mosquito. The vaccine development strategy is termed 
transmission blocking vaccines [61]. These vaccines provide no direct benefit to 
individuals but might fight the disease at the population level. In the vision to 
eradicate malaria completely the inclusion of targets that efficiently block 
transmission are central [62]. 
 
1.4.3 Vaccine development against the erythrocytic stage 
A third vaccine target is the erythrocytic stage, which is the focus of this thesis. 
Vaccines against the erythrocytic stage of the parasite do not aim at preventing 
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infection, but at reducing the morbidity and mortality, particularly among children. 
Targeting blood stage antigens is essential in combination with PE-vaccines. If 
no 100% of protection by a PE-vaccine can be guarantied, individuals in endemic 
areas as well as travelers may be left without any substantial protection against 
the parasite blood stage and may then soon develop severe disease. In endemic 
settings protection against severe disease is acquired rapidly following one or 
two malaria infections. Vaccines that target blood stage parasite could reliably 
prevent severe clinical disease. After a history of disappointing results, the 
current strategies of malaria vaccine development aim at reducing severe 
disease by 50% or more. This level of efficacy is considered to be worth a large 
scale implementation of such a vaccine in malaria control programs [63]. 
 
1.4.4 Blood stage vaccine candidates 
Until now vaccine development against the erythrocytic stages of the parasite 
has focused on proteins mainly localized to the surface of the merozoite, such as 
members of the merozoite surface protein family (MSP1, MSP2, MSP3), to the 
organelles of the apical complex, such as the apical membrane antigen 1 
(AMA1), the proteins of the erythrocyte binding antigens family (EBA175, 
EBA140, EBA181) and rhoptry proteins or to proteins exported by the 
intracellular parasite to the parasitophorous vacuole, the red blood cell or beyond 
(SERA, PfEMP1, EXP1 and GLURP) [63,64,65]. There are currently many blood-
stage candidates approaching clinical evaluation. 
  
One of the few blood-stage vaccines that had undergone a phase IIb field trial is 
Combination B vaccine [66], a subunit vaccine of three recombinant proteins 
MSP1 (C-terminus), MSP2 and RESA. The results of the clinical trial showed that 
the vaccine had significantly reduced the prevalence of parasites with a 3D7-type 
MSP2 and thus corresponding to the vaccine component, but not the prevalence 
of MSP2 forms belonging to the alternative FC27 allelic family [66]. 
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MSP3 has been developed as a long synthetic peptide vaccine (MSP3-LSP with 
alum). A phase-Ib trial conducted in Mali revealed that the vaccine is safe and 
immunogenic. Sera from immunized individuals inhibited in vitro parasite growth 
by the Antibody-dependant cellular inhibition assay (ADCI), [67,68,69]. 
 
Another potential blood-stage vaccine is a combination of the rather conserved 
fragments of AMA1 and MSP1 [70]. A phase I trial in malaria-naive healthy adults 
induced high titer of antibodies. However, biological function of these antibodies 
was not reflected by the in vitro inhibition of parasite growth, and there was 
limited recognition of fixed parasites in an immunofluorescence assay. 
 
Great hopes for an imminent effective malaria vaccine was raised by the first 
SPf66 vaccine trials in the 1990s. The SPf66 vaccine was composed of a 45-
amino-acid long synthetic peptide composed of fragments of three blood-stage 
antigens, of which only one represented a known antigen, linked by the amino 
acids APNANP and PNANP [71]. Early vaccine trials showed vaccine efficacy of 
31% [72], but later trials in Africa and Thailand showed no efficacy and therefore 
the development of this vaccine was suspended. 
 
1.4.5 Major challenges for blood stage vaccine development 
There are many obstacles to the development of efficacious vaccines against the 
blood stage. One is the high degree of polymorphic variability associated with the 
blood stage antigens. It is thought that high levels of polymorphism in malaria 
antigens are part of the parasite’s strategy to escape the host’s immune defense. 
However, by including polymorphic sequences in a malaria vaccine, variant-
specific immune responses will be elicited. As a consequence, alleles distinct 
from the vaccine molecule will be favored by selective advantage giving rise to 
escape variants [66] [73] [74] [75]). In some approaches the frequency of SNPs 
as a signature of selection was used to identify new vaccine targets in known 
antigens [76] or in the entire P. falciparum genome [77]. 
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If a vaccine is designed to induce antibody secretion by B cells, the vaccine 
candidate must mimic the conformation of the parent protein in order to elicit an 
effective antibody response. That creates another obstacle because the 
production of pure and correctly folded recombinant proteins are difficult and the 
antigen structure is often not known. In addition blood stage proteins show a high 
level of functional redundancy.  
 
1.5 Immunity to malaria 
Immune responses against malaria are highly complex and only poorly 
understood. Described immune effector mechanisms include the CD8+ T cell 
response to pre-erythrocytic stages and both the antibody-mediated and CD4+ T 
cell response to the blood stage. 
 
1.5.1 Natural acquired immunity 
Individuals living in malaria endemic regions develop natural acquired immunity 
through repeated infection. This immunity is defined by an age-dependent 
acquisition of non-sterilizing immunity that protects against clinical disease but 
not parasitemia [78]. Natural acquired immunity develops slowly. This is evident 
from the fact that in endemic settings the burden of disease falls on young 
children. The onset of clinical immunity requires 10 to 15 years of roughly five 
infections per year [79]. Distinct hypothesis exist as to the slow onset of clinically 
immunity with direct consequences for malaria vaccine development.  
 
(i) The most widely accepted hypothesis implies parasite diversity as the major 
factor and views natural acquired immunity as the cumulative product of 
exposure to multiple parasite infections over time, resulting in a sufficiently 
diverse repertoire of strain-specific immune responses [79]. A successful vaccine 
should ideally overcome the inadequate response to antigenic diversity.  
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(ii) Another hypothesis suggests that the appropriate immune responses leading 
to natural acquired immunity are governed predominantly by intrinsic 
characteristics that change with age [79]. A successful vaccine should therefore 
overcome an age-dependent inappropriate immune response.  
 
(iii) There is also evidence for the induction of antibodies towards conserved 
epitopes which recognize a broad array of P. falciparum strains [79]. The 
acquisition of these cross-reactive antibodies increases with repeated infections 
and age. In general it was found that conserved antigens are less immunogenic 
than polymorphic antigens [75,80,81,82]. However, it remains to be 
demonstrated that Abs against conserved epitopes are more relevant for 
protection than Abs directed against polymorphic antigens. If that were to hold 
true, then the late onset of clinical immunity could be explained by the poor 
immunogenicity to conserved but relevant antigens. An effective vaccine 
formulation should therefore increase the immunogenicity of these relevant 
antigens. 
 
1.5.2 Importance of innate immunity in malaria infection 
Innate immunity acts as an early line of defense against pathogens. It contributes 
to the control of acute infection by the invading pathogens before the onset of T 
and B cell-mediated immunity. Innate responses are crucial for the stimulation 
and modulation of adaptive immune responses. Natural killer cells (NK) appear to 
play an important role in the early immune response to P. falciparum infection. 
NK activation depends on cytokines released by macrophages and dendritic cells 
(DC) following parasite phagocytosis, but NK are also activated by direct 
interaction with iRBCs, as [83]. NK cells are the first cells that produce interferon 
gamma (IFN-γ) in response to P. falciparum infected RBCs. IFN−γ is the crucial 
link between innate immunity to the adaptive immune system. IFN−γ induces 
further DC maturation and the differentiation of T helper 1 cells. 
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1.5.3 Antibody-mediated responses against blood stage antigens 
The important role of humoral immunity in protection was confirmed by passive 
transfer studies showing that immunoglobulins from clinically immune individuals 
can confer clinical immunity to individuals exposed to geographically diverse 
parasite strains [84,85,86]. Similarly, passively transferred maternal antibodies 
are one factor among others that provide effective protection from clinical malaria 
in newborns. However, opinions diverge on how those antibodies achieve 
protection. The current understanding is that antibodies can mediate protection 
through various mechanisms:  
 
(1) Antibodies block invasion of merozoites into erythrocytes. 
(2) Antibodies prevent sequestration of iRBC by preventing binding to adhesion 
molecules on the vascular endothelium. 
(3) Antibodies trigger the release of parasitostatic and parasitocidal substances 
by monocytes. 
(4) Antibodies neutralize parasite glycosylphosphatidylinositol and inhibit 
induction of the inflammatory cytokine cascade. 
(5) Opsonization and destruction of free merozoites and iRBC by phagocytic 
cells. 
  
1.5.4 T-cell responses against blood stage antigens 
The observation that human CD4+ T cells can inhibit parasite growth in vitro has 
led to the hypothesis that CD4+ T cells acting in an antibody-independent 
manner can control parasite density very effectively. Immunization with low dose 
iRBC followed by drug treatment induced protective immunity against blood 
stage challenge [87]. The protective immunity was characterized by the absence 
of detectable antibodies but by the presence of a T-cell response, involving both 
CD4+ T cells and CD8+ T cells [87]. However, in vivo infection was shown to 
inhibit T cell responses due to overwhelming antigen abundance [88,89].  
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1.6 Alpha-helical coiled-coil motif 
Alpha-helical coiled-coils (CC) share a heptad motif (abcdefg)n containing 
hydrophobic residues at positions a and d and generally polar residues at the 
remaining positions. Chemically synthesized short peptides consisting of such a 
motif can fold into their native structure in aqueous environment. A further 
advantage of CC is that they are recognized by conformation dependent 
antibodies [90]. This is an appealing characteristic and represents a new 
approach to malaria vaccine development. The use of synthetic peptides 
representing conformational epitopes over entire  recombinantly expressed 
proteins in vaccines is advantageous because no elaborate expression and 
purification systems or refolding is required, making the development process 
much less time consuming [91]. CC are highly abundant in the eukaryotic cell. 
They are found in about 10% of all protein sequences [92]. This widespread 
occurrence in nature is explained by the broad range of function pertaining to the 
specific design of CC [93]. The crucial biological function of this domain has been 
investigated in numerous proteins. Generally, CC serve as oligomerization motifs 
in proteins. 
 
1.7 Approach and rational of current thesis 
New malaria blood-stage vaccine candidates were selected in a genome-wide 
approach by screening for alpha-helical coiled-coil domains (CC) using 
generalized sequence profile.  Proteins expressed in the erythrocytic stage of the 
parasite were selected based on publicly available proteome and transcriptome 
data. These analyses led to the identification of 166 protein segments present in 
131 proteins that are associated with the erythrocyte stage and displayed 
putative CC motifs with a high probability score. 95 were chemically synthesized 
and HPLC purified.  
 
The rationale for targeting a coiled coil structural motif lay in the stable tertiary 
structure adopted by these peptides in an aqueous environment. Thus, the 
synthetic peptides corresponding to a coiled coil domain were expected to mimic 
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structurally “native” epitopes. Indeed, the majority of the chemically synthesized 
peptides were specifically recognized by human immune sera obtained from 
adult donors from Burkina Faso, Tanzania and Colombia, respectively, although 
with varying prevalence.  
 
Preceding studies had shown that affinity chromatography purified antibodies 
specific for the 18 most recognized peptides reacted with native parasite proteins 
in infected erythrocytes. 12/18 antibody preparations were active in inhibiting in 
vitro parasite growth in antibody dependent cellular inhibition (ADCI) assays [94]. 
In addition, immunizing mice with these peptides induced antisera reacting with 
native proteins. The chosen approach of bioinformatic selection combined with 
chemical synthesis has led to the rapid identification of molecules that elicit 
functional antibodies, thus identifying suitable vaccine candidates. This 
represents a new strategy to identify novel malaria vaccine candidates.  
 
The research topics of the present thesis are embedded in the frame work of an 
ongoing collaborative project initiated by Prof. G. Corradin from University of 
Lausanne, involving researchers from different fields of vaccinology, such as 
biochemistry (Giampietro Corradin, University of Lausanne, Switzerland), 
immunology (Pierre Druilhe, Pasteur Institute, Paris, France), bioinformatics 
(Andrey Kajava, Centre de Recherches de Biochimie Macromoleculaire, 
Montpellier, France) and clinical trials of malaria vaccines (Socrates Herrera, 
Immunology Institute, Universidad del Valle, Cali, Colombia. 
  
The present thesis is a continuation of previous work of Villard and coworkers 
(2007). The genetic diversity of the CC sequences identified in the course of this 
earlier work became a focus of the current investigations. High levels of 
polymorphism in malaria antigens are thought to be part of the parasite’s strategy 
to evade host’s immune responses and this creates the major difficulty for blood 
stage vaccine development. There is therefore a great demand to identify new 
antigens that are both, immunogenic and conserved.  
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Availability of basic knowledge about vaccine candidates is essential to advocate 
continued preclinical and clinical development and to attract further funding. 
Therefore we investigated in greater detail the most promising candidate, 
PFF0165c (termed Trophozoite exported protein 1 (Tex1)). We performed 
detailed cell biological characterization of Tex1 with respect to subcellular 
localization, expression profile and solubility characteristics during the IDC.  
 
Work performed during this PhD thesis contributed to the immunological 
characterization of the intrinsically unstructured region (P27A) of Tex1 published 
by Olugbile et al. 2009. P27A was meets the principal requirements expected for 
clinical development of a malaria vaccine candidate which is currently under way 
with funding from European Malaria Vaccine initiative (EMVI) (Phase I clinical 
trial). 
 
The ability of peptides to act as potent immunogens has been questioned in the 
past. The wide application as vaccines or drugs now steadily reduces the 
skepticism [95]. To contribute to the validation of vaccines consisting of synthetic 
peptides one of the candidates identified previously (PFD0520c) was now 
recombinant expressed and its serological performance was compared to the CC 
of this protein (P90).  
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1.8 Objectives 
 
1.8.1 General objectives 
Today’s battle against malaria goes beyond controlling the disease. 
Envisioned is a malaria-free world. A substantial contribution to reach this 
goal is the development of an effective vaccine. Vaccine efficacy can be 
increased by targeting all stages of the P. falciparum life cycle. Targeting 
the blood stages of the parasite is essential for aiding populations in 
malaria endemic areas because protective responses against these 
stages could prevent severe clinical disease. This thesis aimed at filling 
the gaps in the preclinical evaluation pathway of novel synthetic peptide 
vaccine candidates. 
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1.8.2 Specific objectives 
 
A. Assessment of sequence conservation of 166 alpha-helical coiled 
coil domains present in proteins expressed in the blood stage of 
P. falciparum based on single nucleotide polymorphism data 
available in PlasmoDB 5.4 database (http://PlasmoDB.org). 
 
B. Assessment of sequence conservation of 14 most promising 
peptides based on pre-clinical evaluation data in additional 13 
culture strains.  
 
C. Assessment of sequence conservation of 5 of these 14 peptides 
in 63 malaria positive field samples from Tanzania and 19 positive 
field samples from Papua New Guinea. 
 
D. Analysis of the subcellular localization of the proteins 
corresponding to the selected peptides by Immunofluorescence 
assay (IFA). 
 
 
E. In depth cell biological characterization of one of the vaccine 
candidates. 
 
F. Validation of the synthetic peptide approach by recombinant 
expression of a protein harboring a coiled coil motif. Comparison 
of serological assays performed using synthetic peptides and 
with those using the corresponding recombinant antigen. 
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Abstract 
 
In a genome-wide screen for alpha-helical coiled coil motifs aiming at 
structurally defined vaccine candidates we identified PFF0165c. This protein 
is exported in the trophozoite stage and was named accordingly Trophozoite 
exported protein 1 (Tex1). In an extensive preclinical evaluation of its coiled 
coil peptides Tex1 was identified as promising novel malaria vaccine 
candidate providing the rational for a comprehensive cell biological 
characterization of Tex1. Antibodies generated against an intrinsically 
unstructured N-terminal region of Tex1 and against a coiled coil domain were 
used to investigate cytological localization, solubility and expression profile. 
Co-localization experiments revealed that Tex1 is exported across the 
parasitophorous vacuole membrane and located to Maurer’s clefts. Change in 
location is accompanied by a change in solubility: from a soluble state within 
the parasite to a membrane-associated state after export to Maurer’s clefts. 
No classical export motifs such as PEXEL, signal sequence / anchor or 
transmembrane domain was identified for Tex1.   
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Introduction 
 
In the past few years Tex1 encoded by PFF0165c was characterized as a 
novel malaria vaccine candidate. According to PlasmoDB version 6.5 
(http://plasmodb.org) tex1 spans nucleotide positions 133’147 to 136’458 on 
chromosome 6. Tex1 had been identified originally in a genome-wide screen 
of alpha-helical coiled coil domains in a search for novel vaccine candidates 
against the blood stage of P. falciparum [1,2]. Chemically synthesized short 
peptides consisting of such a motif can fold into their native structure in 
aqueous environment and therefore mimic structurally native epitopes. Two 
regions of Tex1 were chemically synthesized. One of the synthetic peptides, 
P27, is spanning the coiled coil domain (K845 to T871), the other, P27A, 
corresponds to N-terminal intrinsically unstructured region (H223 to S326). 
Both peptides were tested in an extensive preclinical evaluation protocol to 
analyze the properties of anti-P27 and anti-P27A antibodies regarding in vitro 
parasite killing in presence of monocytes [1,3], correlation with protection in 
adults and children [3,4], prevalence of peptide recognition by sera from semi-
immune adults from different endemic region throughout the world [1,3] and 
sequence conservation in different culture strains and field isolates [3,5]. Both 
fragments of Tex1, peptides P27A and P27, are considered promising novel 
malaria blood stage vaccine candidates. A phase 1 clinical study of P27A is 
scheduled in 2011. 
 
In view of the promising outcome of preclinical evaluation and the imminent 
phase 1 clinical trial, a comprehensive biological characterization of Tex1 was 
called for. Here we present results of a cell biological analysis characterizing 
Tex1 in relation to other known exported parasite proteins. We show that 
Tex1 associates to Maurer’s clefts (MC) membrane facing the cytosol of the 
RBC. Tex1 export depends on the classical secretory pathway. But it seems 
to lack a classical signal sequence as well as a PEXEL motif, suggesting the 
presence of alternative sequences involved in protein export to the PV and 
across the PVM to the RBC cytosol. 
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Material and Methods 
 
Ethical Treatment of Animals 
The animal work has been carried out according to relevant national and 
international guidelines. The immunization experiments in CB6F1 mice and 
the immunization protocol was approved by the Canton de Vaud (Permit 
number: 805.6).  Immunization of rabbits were performed by the commercial 
company Eurogentec, 4102 Seraing, Belgium. 
 
Cell culture and protein extracts.  
P. falciparum 3D7 strain was cultured at 5% haematocrit as described [6], 
using RPMI medium supplemented with 0.5% Albumax [7]. Parasites were 
synchronized with 5% sorbitol [8]. To obtain protein extract of mixed stage 
infected erythrocytes parasites (10 ml petri-dish) were grown to 5% to 10% 
parasitemia, lysed on ice in 0.03% saponin in phosphate-buffered saline 
(PBS, pH 7.4) for 10 min, washed with ice cold PBS for complete removal of 
hemoglobin, and resuspended in Laemmli sample buffer. The protein extracts 
of late-stage parasites (trophozoites and schizonts) were obtained from P. 
falciparum 3D7-infected erythrocytes in a 30-ml petri dish (5% hematocrit, 6% 
parasitemia) which was enriched using a magnetic cell sorter (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The enriched infected erythrocytes were lysed 
in a 200 µl volume of PBS, 0.03% saponin (Fluka) in the presence of protease 
inhibitors (Roche Diagnostics, Basel, Switzerland) for 5 min at 4°C. The 
parasites were pelleted by centrifugation at 4,000 x g for 10 min, the 
supernatant was collected and mixed with sample buffer. The parasite pellet 
was resuspended in 0.1 M Tris, pH 6.8, and an equal volume of 2x Laemmli 
sample buffer. For protein expression profiling 5 ml of tightly synchronized 
culture (2h time frame; 8% parasitemia) was harvested in a 4 hours interval, 
parasites were lysed on ice in 0.03% saponin in PBS for 10 min and wash 3 
times in ice-cold PBS. Parasite pellet was resuspended in cold 0.1 M Tris, pH 
6.8, and an equal volume of 2x Laemmli sample buffer. 
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Recombinant expression and purification of recP27 fragment.  
The C-terminal fragment of Tex1 containing the coiled coil motif P27 (Figure 
1A, M681 to E910) was amplified from 3D7 genomic DNA by PCR and cloned 
into the pQE60 plasmid via the NcoI and BamHI restriction sites (primers used 
are listed in Table S1). Recombinant expression was performed following the 
manufacturer’s protocol (Qiagen Inc.).  
 
Generation of anti-P27, anti-P27A and anti-recPf27 polyclonal rabbit sera 
and anti-P27 polyclonal mouse sera.  
Rabbit sera were produced by Eurogentec, Seraing, Belgium. In short, the 
recPf27 protein (250 µg) was used for immunization with Freud’s adjuvant into 
two New Zealand white rabbits. Sera samples (20 ml) were affinity purified 
using recPf27-6xHis protein or the P27 coiled coil peptide coupled to HiTrap 
NHS-activated HP columns (GE-Healthcare, 1 ml). After antibody binding 
columns were washed with 50 ml PBS, bound IgG was eluted with 0.1 M 
glycine, pH 2.5, and the buffer was subsequently changed to PBS using 
HiTrap Desalting Columns (GE Healthcare). Purified antibodies were stored at 
−80°C until further use. Polyclonal mouse sera was obtained by immunization 
of CB6F1 mice. CB6F1 mice were injected 3 times with 20 µg of the P27 
peptide in Montanide ISA 720 at the base of the tail on day 1, 22 and 78. 
Bleeding was performed 10 days after the second and third immunization. 
Affinity purification of P27A-specific rabbit has previously been described 
[1,3]. 
 
Western blot analysis.  
Protein extracts were separated on a 10% sodium dodecyl sulfate-
polyacrylamide gel and transferred to nitrocellulose (Hybond-C extra; GE 
Healthcare) at 4°C for 1 h at 80 V and an additional hour at 100 V. The 
membrane was blocked for 1 h in 5% skim milk, 0.1% Tween in Tris-buffer. 
Antibodies used were: Polyclonal rabbit anti-P27A (1:5000); anti-P27 (1:2500) 
and anti-Pf27rec (1:2500); anti-MAHRP1 (1:5000), monoclonal mouse anti-
MSP1 ([9], 1:1000); anti-SERA5 ([10], 1:2000); horseradish peroxidase-
conjugated goat anti-mouse (Pierce, 1:20 000), goat anti-rabbit (Acris, 
1:10000).  
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Solubility analysis.  
P. falciparum 3D7-infected erythrocytes (30-ml petri dish; 6% parasitemia) 
were enriched using a magnetic cell sorter (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Purified mature stages were resuspended in 200 µl 
5mM Tris pH 8 in the presence of protease inhibitors (Roche Diagnostics, 
Basel, Switzerland) and lysed by 3 freezing-thawing cycles. Soluble protein 
fraction was separated by centrifugation 30 min at 20 000xg at 4°C. The 
membrane-containing pellet was resuspended in 200 µl 0.1 M Na2CO3 and 
incubated for 30 min on ice to extract peripheral membrane proteins. 
Supernatant containing peripheral proteins was separated by centrifugation 
(30 min at 20 000xg at 4°C). Integral membrane proteins were extracted from 
the pellet with 1% Triton X-100 on ice for 30 min. Supernatant containing 
integral proteins was separated by centrifugation (30 min at 20 000xg at 4°C) 
The remaining proteins were extracted with 4% SDS, 0.5% TritonX-114 in 
0.5x PBS for 30 min at room temperature and separated from the pellet by 
centrifugation. The supernatant was analyzed as insoluble protein fraction. 10 
µl of each fraction was analyzed by Western Blot. 
 
RNA isolation, cDNA synthesis and real time PCR 
3D7-infected erythrocytes were tightly synchronized using 5% D-sorbitol [8]. 
Three rounds of 5% D-sorbitol treatment was applied (2nd and 3rd treatment 
was applied 8 hours and 14 hours after the 1st D-sorbitol treatment). Parasites 
were grown to 8-10% parasitemia (5% heamatocrit). 1.5 ml culture was taken 
in 4h intervals. In brief, parasite RNA was extracted using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. TRIzol extraction was repeated. 
Residual gDNA was digested twice with RQ1 DNase (Promega) according to 
the manufacturer’s protocol. Reverse transcription was done by AffinityScript 
Multiple Temperature Reverse Transcriptase (Stratagene) with random 
primers (Invitrogen) as described by the manufacturer. To control for gDNA 
contamination, the target sequence was amplified from the RNA solution prior 
to reverse transcription. Absolute transcript quantification was performed at 
final primer concentrations of 0.4 µM using SYBR® Green Master Mix (Applied 
Biosystems) on a StepOnePlusTM Real-Time PCR System (Applied 
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Biosystems) in a reaction volume of 12 µl. All reactions were performed in 
triplicate yielding virtually identical Ct values. A serial dilution of gDNA was 
used as standard for absolute quantification. Relative transcript profiles were 
calculated by normalization against transcript levels of the house-keeping 
gene PF13_0170 (glutaminyl-tRNA synthetase). Validation of synchronization 
procedure was obtained by analyzing transcript levels of the merozoite 
surface protein 8 (msp8). The primers used for qPCR of tex1, PF13_0170 and 
msp8 are shown in Table S2. The time points of harvest (1-14), the 
corresponding age of parasites (in hours post infection) and the 
corresponding parasite stages are illustrated in Table 1 and were confirmed 
by Giemsa staining before RNA and Protein extraction.  
 
Indirect Immunofluorescence Assay (IFA). 
Infected erythrocytes were fixed with 4% paraformaldehyde (Polyscience) and 
0.0075% glutaraldehyde (Polyscience) for 30 min under constant agitation, 
permeabilized using 0.1% Triton X-100/PBS for 10 min and blocked with 
sodium borohydride (NaBH4)/PBS for 10 min followed by an additional 
blocking step using 3% BSA in PBS for 1 h as described in [11]. Primary 
antibodies were used with the following concentrations: polyclonal rabbit sera 
anti-P27A (1:2000); anti-P27 (1:1000), anti-MAHRP2 ([12], 1:100); anti-REX1 
(kind gift from Prof. Don Gardiner, 1:500); mouse polyclonal antibodies anti-
P27 (1:200); anti-SBP1 N-terminus specific (kind gift from Prof. Catherine 
Braun-Breton, 1:200); anti-MAHRP1 (1:200). Secondary antibodies used: 
Alexa Fluor 488 (Invitrogen; 1:400); Texas Red (Invitrogen; 1:400). Cells were 
mounted in Vectashield Hard Set supplemented with DAPI (Vector 
Laboratories) for staining of the nuclear DNA. For the Equinatoxin II assay 
infected erythrocytes were lightly fixed with 2% paraformaldehyde in RPMI 
medium (10 min), permeabilized with Equinatoxin II [13], and re-fixed with 4% 
formaldehyde and 0.00075% glutaraldehyde in PBS (pH 7.4, Gibbco). Cells 
were blocked with 3% BSA (Sigma) in PBS. Cells were split and one half was 
additionally treated with 0.1% triton (Merck) for complete permeabilization. 
Synchronized Ring stage parasites (aged 4h to 8h post invasion) were treated 
with Brefeldin A solved in 100% ethanol (Fluka) to a final concentration of 
5 µg ml−1. Control cultures were incubated in the presence of equivalent 
CHAPTER 4: CELL BIOLOGICAL CHARACTERIZATION OF TEX1 
 
 68 
amounts of ethanol. After 18 h parasites were fixed for IFA. BFA was removed 
from the remaining parasites which were further cultured to ensure viability 
after treatment. Images were obtained by the Zeiss confocal microscope LSM 
700 or Leica DM 5000B fluorescence microscope. Images were processed by 
ImageJ software or the Huygens Essential Software (Scientific Volume 
Imaging, The Netherlands). Quantitative analysis of co-localization was done 
with Huygens Essential Software (Scientific Volume Imaging, The 
Netherlands). 
 
 
Results 
 
According to PlasmoDB version 6.5 (http://plasmodb.org), the predicted 
protein has a length of 1103 amino acids (aa) and contains 3 predicted coiled 
coil domains. Alpha-helical coiled coils share the heptad motif (abcdefg)n with 
positions a and d representing hydrophobic residues,  whereas the remaining 
positions are generally polar. Depending on slight variations in their 
sequences the coiled coil bundles consist of 2 to 7 alpha-helices that 
spontaneously self assemble in aqueous solutions. One of the 3 coiled coil 
domains in Tex1 is the P27 region from position K845 to T871 (in black, 
Figure 1A.), which has been identified as potential malaria vaccine candidate 
previously [1]. The C-terminus of Tex1 consists of a predicted RING (Really 
Interesting New Gene) domain, spanning amino acids K1025 to L1102 (in 
grey, Figure 1A). Furthermore, a large portion of the C-terminal half of this 
protein (650-1040) has sequence similarity to several proteins with known 3D 
structure which have elongated alpha-helical domains capped by the RING-
domains (e.g. [14]. This supports correctness of our previous prediction of 
alpha-helical coiled coil regions in Tex1 (Villard et al., 2007). A long 
intrinsically unstructured region (IUR) named P27A, ranging from position 
H223 to S326 (black dotted, Figure 1A), corresponds to the second identified 
potential vaccine candidate within Tex1 [3]. P27A is currently under clinical 
development and a phase 1 clinical trial is scheduled for 2011. 
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Tex1 is expressed in intraerythrocytic blood stage parasites and its 
transcription is up-regulated in the early trophozoite stage. 
In order to characterize the protein by IFA and Western Blot, rabbit antibodies 
were generated against P27A and a 240 aa long (including linker and His-tag) 
recombinant protein (recPf27) encompassing amino acid M681 to E910 
(Figure 1A) in the C-terminal part of Tex1 and including the P27 coiled coil 
domain (K845 to T871). Both polyclonal rabbit sera were affinity purified on 
the respective immunogens. In addition, recPf27 rabbit serum was 
alternatively affinity purified on the P27 peptide. Thus, three polyclonal rabbit 
sera were available with specificities to P27A, recPf27 and P27. 
 
Previously, we showed that P27A specific mouse and rabbit sera both 
detected a protein with the mass of 160 kDa in Western Blot broadly 
consistent with the predicted mass of 132 kDa [3]. When using several sera 
raised against different parts of Tex1, all sera recognized a band at about 
160kDa both, in the pellet fraction of mixed parasite stages and in late stage 
parasites (Figure 1B).  
 
The transcription profile was analyzed by quantitative real-time PCR on RNA 
from tightly synchronized cultures harvested in 4 h intervals covering the 48h 
intra-erythrocytic developmental cycle. The collected time points, the 
corresponding age of the parasites (in hours post invasion) and the respective 
parasite stages are listed in table 1. The transcription level of tex1 was 
analyzed in relation to that of a constitutively transcribed gene, glutaminyl-
tRNA synthetase (PF13_0170). Tex1-specific transcripts were detected 
throughout the intra-erythrocytic development cycle, but an up-regulation of 
transcript abundance was detected in early trophozoites (gray bars, Figure 
1C). To validate the synchronization procedure, transcript levels of the 
merozoite surface protein 8 (msp8) were analyzed at each time point. The 
msp8 profile obtained (white bars, Figure 1C) showed an up-regulation in ring 
stages and in very late schizont stages as shown in PlasmoDB. The RNA 
levels of tex1 were compared with a time course of Tex1 protein abundance 
analyzed by Western Blot during the intra-erythrocytic cycle. Tex1 protein 
levels detected in 4 h intervals were highest during early trophozoite stage at 
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time point 8 (Figure 1D). The protein persisted until egress, reflected. in the 
presence of the full length merozoite surface protein 1 (MSP1) [15].  
 
Tex1 is exported to the host cell cytosol and localizes to Maurer’s clefts.  
Previously we reported that Tex1 was exported and accumulated at structures 
in the cytosol of the infected RBC [3]. To study the exact subcellular 
localization of Tex1 during the intra-erythrocytic cycle, synchronized 3D7 
parasites were analyzed by IFA. In early ring stages (0-6 hours post invasion) 
the protein was absent (data not shown), whereas in late ring stages (12-16 
hours post invasion) Tex1 was detected in punctuated structures within the 
parasite (Figure 2A). In trophozoite stages, Tex1 is exported to the host cell 
cytosol and associates with elongated structures in the cytosol of the infected 
RBC (Figure 2B) suggestive of Maurer’s clefts (MC) staining [16]. In schizont 
stages the protein was much less focused and seemed to associate to the 
periphery of the host cell in vicinity to the host cell membrane (Figure 2C). 
 
To prove the localization to MC, co-localization experiments were performed 
using antibodies against known MC markers. In late ring stages the ring 
exported protein 1 (Rex1) (Figure 3A), SBP1 (Figure 4A) and MAHRP1 
(Figure 5A) associated with MC, whereas Tex1 still remained within the 
parasite. In trophozoite, schizont and late schizont stages, Tex1 appeared to 
associate with MC as demonstrated by co-localization with Rex1 (Figure 3B, 
3C, 3D), SBP1 (Figure 4B, 4C) and MAHRP1 (Figure 5B and 5C. In schizont 
stages Tex1 signal was detected similar to Rex1 adjacent to the RBC 
membrane. Tex1 was also detected in close proximity to new structures called 
tethers (Figure 6A) that are characterized by the membrane-associated 
histidine rich protein 2 (MAHRP2, [12]. However, Tex1 is not found anymore 
in close proximity to MAHRP2 in schizont stage parasites (Figure 6B). 
Antibodies directed against Tex1 failed to detect the protein at the surface of 
infected RBCs in unpermeabilized cells (Figure S1) suggesting that in 
schizonts the protein resides inside of the infected cell in close proximity to 
the RBC membrane. 
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Tex1 occurs in two conditions: as soluble protein and in association 
with membrane structures. 
Late parasite stages were purified by magnetic cell sorting and were lysed by 
repeated freeze thaw cycles to release all soluble proteins of the parasite and 
the RBC. The peripheral, membrane-associated proteins were extracted from 
the pellet fraction containing the membranes by sodium carbonate buffer (pH 
11). The remaining integral membrane proteins were extracted with Triton X-
100. This fractionation revealed that Tex1 was partly found soluble but equal 
amounts of the protein could only be extracted by carbonate buffer indicating 
that Tex1 associated with membranes (Figure 7). As control for the integrity 
of our fractions we used monoclonal antibodies against serine-rich antigen 5 
(SERA5), a soluble protein found in the PV [17,18,19]; MAHRP1 was used as 
control representing an integral membrane protein [20,21]; MSP1 served as 
control representing a glycosylphosphatidylinositol lipid anchored protein on 
the merozoite surface and also as marker for the integral membrane fraction 
[22]  
 
In order to analyze the localization of Tex1 at the MC, infected RBCs were 
lysed with Equinatoxin II (EqtII), a pore-forming toxin binding preferentially to 
sphingomyelin-containing membranes [13]. It lyses the RBC membrane 
ensuring integrity of PVM and MC membranes [23]. SBP1 is an integral 
membrane protein localizing to MCs. The C-terminus of SBP1 is directed to 
the RBC cytosol, whereas the N-terminus is directed to the lumen of MCs.  
The upper panel of Figure 8 shows Tex1 localization in EqtII lyzed parasite 
infected RBC. In these EqtII treated parasites the N-terminus of SBP1 is not 
detected because antibodies specific to this part cannot access their target 
due to intact MC membranes.  
 
SBP1 staining was performed to demonstrate the integrity of the MC 
membrane. P27-specific antibodies detected Tex1 in cells treated with EqtII at 
the MC. This demonstrated the localization of Tex1 at the surface of MC 
facing the RBC cytosol (Figure 8).  
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In the lower panel of Figure 8, the parasites were further lyzed with Triton X-
100, which permeabilized also the MCs membrane, therefore SBP1 can be 
detected with antibodies directed against the N-terminus of the protein 
(Figure 8). 
 
Export of Tex1 is Brefeldin A sensitive. 
Protein secretion pathways in the eukaryotic cell are classified into the 
classical and nonclassical secretory pathway as reviewed by [24]. Whereas 
the classical secretory pathway involves co-translational translocation of 
proteins into the ER or posttranslational insertion into the ER followed by 
vesicular transport from the ER via Golgi to the cell surface or the extracellular 
space reviewed in [25], the molecular mechanisms involved in the 
nonclassical protein secretion are independent of the ER/Golgi system 
[26,27]. To test by which route Tex1 is exported, infected RBCs were treated 
with Brefeldin A (BFA), a fungal metabolite shown to block the classical 
protein secretion pathway [28]. BFA treatment blocked Tex1 export (Figure 9) 
suggesting that Tex1 export depends on components of the classical 
secretory pathway. 
 
 
Discussion 
 
Extensive preclinical evaluation of the annotated hypothetical protein Tex1 
revealed that two regions, the intrinsically unstructured region P27A and the 
coiled coil domain P27, show great potential as new malaria vaccine 
candidates [1,3,5]. Its clinical development, currently in phase 1, called for an 
in depth analysis of the cytological characteristics of Tex1, which was named 
“Trophozoite exported protein 1” due to its localization to MC at the 
trophozoite stage. Association to MC was confirmed by co-localization with 
Rex1 and other MC proteins. Tex1 associated with the MC membranes facing 
the cytosol of the RBC. This was demonstrated by EqtII lysis of infected 
RBCs, which in contrast to Triton X-100 permeabilizes exclusively the RBC 
membrane. While antibodies detected Tex1, other antibodies, directed against 
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the luminal N-terminus of SBP1, could not access the lumen of MCs and thus 
gave no signal.  
 
Exported proteins in P. falciparum are classified based on the presence or 
absence of the PEXEL motif which is mostly located downstream of a 
hydrophobic stretch. Recently, an increasing number of PEXEL-negative 
exported proteins (PNEPs) were identified [12,16,29,30]. Tex1 also is a 
PEXEL negative exported protein. To date it is only poorly understood how 
PNEPs are trafficked across the PVM, and sequence signatures responsible 
for export across the PVM and to the MC remain to be identified, if these exist 
at all.  
 
A common characteristic of PNEPs seems to be the presence of either N-
terminal signal sequence or a transmembrane domain [31]. For Tex1 no 
classical signal sequence, nor PEXEL motif, could be identified. The Tex1 
expression pattern varies from that of PNEPs. Whereas Tex1 is expressed in 
trophozoites, PNEPs are expressed early in the intra-erythrocytic 
developmental cycle. We identified a potential alternative start site at position 
- 43 in respect to the predicted translational start site (PlasmoDB, Figure S2). 
This stretch of 43 aa was predicted by SignalP 
(http://www.cbs.dtu.dk/services/SignalP/) to function as signal anchor and is 
unique for P. falciparum Tex1. No such preceding sequence stretch was 
detected in the orthologues of P. vivax (PVX_113335) and P. knowlesi 
(PKH_114650, Figure S2). Constructs of Tex1 including a GFP tag at the C-
terminus were generated with or without the 43 aa hydrophobic stretch and 
episomally expressed. However, the GFP signals of both variants remained 
inside the parasite. More experimental data is needed to further investigate 
sequences responsible for Tex1 export. GFP-tagging of Tex1 might have 
interfered with the function of the RING domain at its very C-terminus. This 
would suggest that the RING domain plays an important role in Tex1 export. 
Brefeldin A treatment resulted in the accumulation of Tex1 at close proximity 
to the nucleus suggestive for ER or ER exit sites, indicating the involvement of 
the classical secretory pathway in the export of Tex1. 
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Tex1 exhibited a differential solubility pattern, whereby a portion of the protein 
was found in the soluble fraction, while the rest was present as peripheral 
membrane protein. No soluble Tex1 was detected in the RBC cytosol or PV, 
as demonstrated in the fractionation experiment using saponin lysed infected 
RBCs (Figure 1B), suggesting that the soluble pool of Tex1 is present 
exclusively within the parasite. This finding suggests that Tex1 changes its 
solubility during export: Tex1 is exported as a soluble protein, but associates 
with MC membranes after export. Our solubility assay showed equal amounts 
of soluble Tex1 and membrane-associated Tex1. However, the soluble 
portion likely is overrated due to freeze/thaw-mediated release of Tex1 from 
its MC’s association. 
 
Also for other proteins a solubility change after export has been reported, e.g. 
for  Rex1 [32]. Similar to Tex1, Rex1 was found to associate with MCs via 
protein-protein interaction [32]. Rex 1 has a predicted transmembrane domain 
and its alpha-coiled coil region (amino acids 160-370) seems to be 
responsible for MC association [32]. Tex1 contains three putative coiled coil 
domains (Table S3). The alpha-helical coiled coil motif is a very abundant 
protein motif present in around 10% of all proteins [33]. Coiled coils have 
been shown to function as protein-protein interaction sites and to be involved 
in oligomerization and complex formation [34]. Thus, coiled coils participate in 
many cellular processes, such as membrane fusion, vesicular trafficking and 
cell motility. Further experiments are needed to elucidate the function of Tex1 
coiled coil domains for MC membrane association. 
 
Also for PfEMP1 a change in solubility during export had been reported [35]. 
Despite the presence of a transmembrane domain, PfEMP1 seems to be 
synthesized as a carbonate extractable protein. After export PfEMP1 
becomes increasingly insoluble [35]. 
 
Noteworthy was the observation of very good co-localization of both 
peripheral membrane proteins Tex1 and Rex1, in contrast to the 
incomplete/partial co-localization of Tex1 with the integral membrane proteins 
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MAHRP1 and SBP1 at MC’s. This provides further evidence for a peripheral 
membrane association of Tex1. 
 
We investigated, whether the export of Tex1 is influenced by other exported 
proteins. Tex1 export was not altered in D10 parasites (data not shown), 
which have a partial deletion of chromosome 9 and a truncation of 
chromosome 2, eliminating 22 genes, including Rex1, 2, 3, 4 and KAHRP, 
and resulting in loss of cytoadherence [36,37,38,39] and alteration of the MC 
structure [40,41]. Similarly, in MAHRP1 knock out parasites, where PfEMP1 
trafficking to the RBC membrane is blocked [16], Tex1 was correctly exported 
and its association with the MC remained intact  (data not shown). 
 
Tex1 orthologues were found in P. vivax and P. knowlesi as well as in P. 
berghei, P. chabaudi or P. yoelii. P27 was highly conserved among 
Plasmodium species (Figure S3A). Interestingly, the unstructured region was 
present exclusively in P. falciparum (Figure S3B). Many of the other ring 
stage exported proteins of P. falciparum, such as MAHRP1 and 2, SBP1 and 
Rex1, 2, 3, and 4, as well as the resa-multi gene family, do not have 
orthologues in P.vivax. Discrepancies were found also in a comparison of P. 
falciparum and P. vivax transcription profiles [42]. Eleven percent of syntenic 
genes of P. vivax and P. falciparum differed in gene expression during the 
intra-erythrocytic developmental cycle [42]. Similar results were obtained for 
tex1 transcripts. According to PlasmoDB the P. vivax orthologue showed a 
completely different transcriptional profile with transcripts up-regulated in ring 
stage parasites suggesting a divergent evolution of Tex1 function. 
 
Antibodies directed against P27 and P27A of Tex1 were effective in in vitro 
parasite killing in the presence of monocytes [1,3] and both P27 and P27A 
were recognized by serum from semi-immune adults from various endemic 
settings [1,3]. These results suggested that Tex1 holds a crucial 
immunological function. However, we found that Tex1 was absent on the 
surface of the infected RBC. The effector function of Tex1-specific antibodies 
excludes therefore blocking of cytoadherence or opsonization and destruction 
of iRBC by phagocytic cells, but involves monocytes. We conclude that the 
CHAPTER 4: CELL BIOLOGICAL CHARACTERIZATION OF TEX1 
 
 76 
activation of monocytes by P27/P27A-specific antibodies may occur after 
parasite egress. 
 
The persistence of Tex1 until egress could indicate functional activity   at the 
end of the 48 h blood stage cycle. To elucidate the biological function of Tex1, 
we attempted to knock-out tex1. These attempts failed indicating that the tex1 
locus resists recombination events due to an essential role of Tex1 for 
parasite survival. 
 
Conclusion 
Tex1 was identified based of extensive preclinical evaluation as promising 
novel vaccine candidate against P. falciparum blood stage infection. In the 
past, malaria blood-stage vaccine development has focused on antigens 
located on the surfaces of iRBC or free merozoites. This approach assumed 
that protective antibodies would opsonize, block invasion or prevent 
sequestration. Tex1 was not found to be surface exposed, but instead 
localized to the surface of MC. Upon egress, Tex1 gets exposed to the host 
immune system. A Tex 1-specific antibody effector function remains to be 
elucidated, but likely involves the presence of monocytes. 
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Figures: 
 
 
 
Figure1: Tex1 structure and expression dynamics on transcriptional and 
protein level. A) Schematic representation of Tex1. Black dotted: intrinsically 
unstructured region P27A; Black: coiled coil domain P27; grey: RING motif. B) 
Western Blot analysis of antibodies specific for P27A and P27 on the pellet 
fraction after saponin lysis of mixed stage parasite (M) and late stage parasite 
(LS). The late stage parasites were fractionated into a supernatant (SN) and a 
pellet (P) fraction after saponin lysis. M: marker C) Abundance of tex1 
transcripts by gRT-PCR. RNA was isolated from tightly synchronized culture 
in a 4h interval (table 1). Tex1 transcript levels (grey bars) were normalized to 
the transcript abundance of the constitutively expressed glutaminyl-tRNA 
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synthetase (PF13_0170). As a control for the level of synchronization msp8 
transcripts were measured and compared to the PF13_0170 transcript level 
(white bars). D) Protein level was analyzed throughout the intraerythrocytic 
development cycle in a 4h interval by Western Blot analysis using antibodies 
against P27A and compared to protein abundance of MSP1. The parasite age 
(in hours post infection) and the parasite stages (confirmed by Giemsa 
staining) corresponding to the time points of harvest are illustrated in table 1.  
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Figure 2: Immunofluorescence staining of erythrocytes infected by P. 
falciparum (ring, trophozoites and schizont stages) using P27-specific 
polyclonal rabbit sera. P27-specific polyclonal rabbit sera was used to 
detect Tex1 (green) A) in late ring stages B) in trophozoite stages C) in 
schizont stages. Nucleus stained with DAPI (blue), transmission picture of the 
infected red blood cell (DIC) and merged picture of the two signals or the 
signals merged with transmission picture (merge), Scale bar: 5 µm. 
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Figure 3: Co-localization of Tex1 with Rex1. P27-specific polyclonal mouse 
sera (in red) was used to detect TEX1. Rex1 polyclonal rabbit sera (in green). 
(A) Ring stage parasites; (B) trophozoite stages; (C) schizont stages. Scatter 
plots show the degree of co-localization of the Tex1 with Rex1 signal. Nuclear 
DNA was stained with DAPI (blue), Transmission image (DIC), Scale bar: 5 
µm. 
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Figure 4: Co-localization of Tex1 with SBP1.  P27-specific polyclonal rabbit 
sera was used to detect Tex1 (red). Co-localization was performed using 
SBP1 polyclonal mouse sera (green). Co-localization was performed in ring 
(A) trophozoite (B) and schizont stage (C) infected RBCs. Nuclear DNA was 
stained with DAPI (blue), Transmission image (DIC), Scale bar: 5 µm. 
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Figure 5: Co-localization of Tex1 with MAHRP1.  P27-specific polyclonal 
rabbit sera was used to detect Tex1 (red). Co-localization was performed 
using MAHRP1 polyclonal mouse sera (green). Co-localization was performed 
in ring stage (A) trophozoite (B) and schizont stage (C) infected RBC. Nuclear 
DNA was stained with DAPI (blue), Transmission image (DIC), Scale bar: 5 
µm. 
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Figure 6: Tex1 localization in trophozoite and schizont stages with 
respect to newly described structures called tethers. Co-localization of 
Tex1 (red) with MAHRP2 (green) A) in trophozoite stages and B) in schizont 
stages. Nuclear DNA was stained with DAPI (blue), Transmission image 
(DIC), Scale bar: 5 µm. 
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Figure 7: Dual solubility pattern of Tex1 shown by Western blot analysis 
of membrane fractionation assay of late stage parasites. Soluble proteins 
from membranes of RBCs infected with late stage parasites lysed by freezing 
thawing cycles (lane 1). Peripheral membrane proteins extracted by sodium 
carbonate buffer, (lane 2). Integral membrane proteins obtained by additional 
1% Triton X-100 extraction (lane 3). Insoluble proteins (remaining membrane 
proteins after Triton X-100 extraction (lane 4). Blot was probed with P27A-
specific polyclonal rabbit sera (panel 1), anti-MAHRP1 polyclonal rabbit sera 
(panel 2) and SERA5 and MSP1 mouse monoclonal antibodies (panel 3).  
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Figure 8: Equinatoxin II assay. A) 3D7 infected RBC lysed with equinatoxin 
II. Integrity of MCs is demonstrated by the absence of the SBP1 signal after 
using SBP1 N-terminus specific polyclonal mouse sera (note: N-terminus of 
SBP1 faces the lumen of MCs). Tex1 signal on the MC surface was obtained 
with P27-specific polyclonal rabbit sera (in green). B) 3D7 infected RBC lysed 
with equinatoxin followed by Triton lysis. MC lumen is now accessible for 
antibodies as shown by the SBP1 signal (in red). Nuclear DNA stained with 
DAPI (blue), Transmission image (DIC). Scale bar: 5 µm. 
 
 
 
 
 
Figure 9: Brefeldin A sensitivity of Tex1 export. 3D7 infected RBC were 
treated with BFA and fixed (+BFA). Tex1 was stained using P27 or P27A-
specific mouse antibodies (in red, upper panel: early trophozoite, middle 
panel: trophozoite). Tex1 visible inside the parasite in close proximity to the 
nucleus. A control culture (+ETOH) was incubated with equivalent 
concentration of ethanol, the solvent of Brefeldin A. In the control culture Tex1 
was correctly exported and associated to MC (in red). The nucleus was 
stained with DAPI (in blue). Transmission image (DIC). scale bar: 5 µm 
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Tables 
 
Table 1: Time points of harvest of synchronized 3D7 in vitro culture.  
 
Time points Hours post infection Parasite stage 
1 46-48 Schizont / Ring 
2 0-2 Schizont / Ring 
3 4-6  
Ring 4 8-10 
5 12-14 
6 16-18 Late Ring 
7 20-22 Early Trophozoite 
 8 24-26 
9 28-30 Trophozoite 
 10 32-34 
11 36-38 Late Trophozoite 
12 40-42 Late Trophozoite / 
Schizont 
13 44-46 Schizont 
14 48-50 Schizont / Ring 
 
Synchronized P. falciparum 3D7 parasite culture were harvested in 4 hours 
interval. Time points of harvest 1-14 (column 1), the corresponding age of 
synchronized parasites at each time point of harvest (in hours post invasion, 
column 2) and the corresponding parasite stage (column 3). 
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Supporting Information: 
 
 
 
Figure S1: Absence of surface exposure of Tex1. The absence of Tex1 
from the surface of infected RBCs was shown by incubating live cells with 
P27-specific polyclonal mouse sera directed against Tex1 (panel A). Tex1 
signal was detected only in a lysed cell (panel A, white arrow). Nucleus 
stained with DAPI (panel B). Merged pictures of both signals and the 
transmission image (panel C). Scale bar: 5 µm 
 
CHAPTER 4: CELL BIOLOGICAL CHARACTERIZATION OF TEX1 
 
 90 
 
 
Figure S2: Upstream region of Tex1 and its orthologues in P. vivax 
(PVX_113335) and P. knowlesi (PKH_114650). Sequence highlighted in 
gray represents the region upstream of the  of the predicted start Methionine. 
Stars (*) represent stop codons.  
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P.falciparum FNEESKSEEGKIQLRDIQNDNDEKYDDEKKRFKELFIENQKLKEELNKKRNVEEELHSLR
P.vivax CDELVAAPGADLHS-------------------ELLVENKQLKRALEKKQNAEKELSVLK
:* : ..:: **::**::**. *:**:*.*:** *:
P.falciparum KNYNIINEEIEEITKEFEKKQEQVDEMILQIKNKELELLDKFNNKMNKAYVEEKLKELKN
P.vivax KNYDAMSEEIEEITKEFEKKQEQVDEMIIQIKNKEFESLEKYKNAMNKICVEENIQQLER
***: :.*********************:******:* *:*::* *** ***::::*:.
P.falciparum TYEEKMKHINNIYKKHDDFVNIYLNLFFQARKNAILSDSQREEQMNLFIKLKDKYDIIFQ
P.vivax SYQEKVSSINRLYEKYESFAHVYLTLFYYARRSAVLSDSAREEQMSLFIKMKDKCESIFQ
:*:**:. **.:*:*::.*.::**.**: **:.*:**** *****.****:*** : ***
P.falciparum KKIELTDILKNVYDCNKKLIGHCQDLEKENSTLQNKLS----------------------
P.vivax RKNELAEILQTVYGSNRKLMDKCNALYRENQHLERVATPTGGKGRRDPKDASCKGEAKRA
:* **::**:.**..*:**:.:*: * :**. *:. :
P.falciparum ---------NEIKNSKMLSKNLSKNSDDHLLIEENNELRRRLICSVCMENFRNYIIIKCG
P.vivax GAEEDADEADEADEADQADQGEEELEERQLLIEENNELRRRLMCSVCMENFKNYIIVKCG
:* .::. .:. .: .: :*************:********:****:***
P.falciparum HIYCNNCIFNNLKTRNRKCPQCKVPFDKKDLQKIFLD
P.vivax HIYCESCIFSNLKTRNRKCPQCKIPFDKKDLQKIFLD
****:.***.*************:*************
A
P.falciparum MPNFYIHDIITSFWFSISNIYIYIYICTYFIISFFCLFSIYKIMSNKKRSKNENDESTSL
P.vivax -------------------------------------------MNSKKRNRSGKSECITL
*..***.:. :.*. :*
P.falciparum PLENSELLIEYIHNLKSCLNVYRREIQEKNKYISIIKNDLSFHECILTNVNVVWSVFNND
P.vivax PLEKTELLIENIYNLRNAISLYRKELQEKNKCISDVKGELTFYECLLSNVSVVWGVFNDD
***::***** *:**:..:.:**:*:***** ** :*.:*:*:**:*:**.***.***:*
P.falciparum LLNLLCNNEQKEEGEEIIKQRNIGDEINEYNNLTKLQNDENIKNNNMIKEDLEDDANQNI
P.vivax LLRLAGEEGAIGDG------RCDGGGVGAVGGDCGDCGDPRCDG----AGQAQPSTGHCK
**.* :: :* * *. :. .. .* . .. : : .:.:
P.falciparum LMKSPYYNIENFLQVFLKYINKKKKKVKVKVKDEGKKEKIEDKKYEQDDEEENEEEEEEE
P.vivax GAAAPYYDVEQFKRIFLKYVSKNN---------------------QESDEEEDSQFSEAP
:***::*:* ::****:.*:: ::.****:.: .*
P.falciparum EEEEGEEENKEDEEFFKTFVSFNLYHNNNEKNISYDKNLVKQENDNKDEARGNDNMCGNY
P.vivax SEDDACGEGKG-------------------------------------------------
.*::. *.*
P.falciparum DIHNERGEMLDKGKSYSGDEKINTSDNAKSCSGDEKVITSDNGKSYDYVKNESEEQEEKE
P.vivax ------------------------------------------------------EVEERG
* **:
P.falciparum NMLNNKKRSLECNPNEAKKICFSLEEKIGTVQSVKLKEYNELSKENIEKNKHDDNNICNY
P.vivax GLPNGGAIKGEPLPGDLKKSQKSKEAVCGKDKERSRKQRNEFSSSKEE--THLEGEAAQK
.: *. . * *.: ** * * *. :. . *: **:*..: * .* :.: .:
 
 
Figure S3: Sequence alignment of the P. falciparum Tex1 with the P. 
vivax orthologue. 
A) Sequence alignment of the Tex1 C-terminus, P27 highlighted in grey. B) 
Sequence alignment of the Tex1 N-terminus, predicted signal sequence 
highlighted in light grey; P27A highlighted in bold. 
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Table S1: Oligonucleotide sequences used for cloning (restriction sites 
in bold) 
 
Fragment Forward primer 5’-3’ Reverse primer 5’-3’ 
recPf27 GATCCCATGGATGGAAAATAAAAAGG
ATGAAG 
GATCGGATCCCTCTTCTACATACGCTTTA 
   
 
Table S2: Oligonucleotide sequences used for qRT-PCR Table S2: Oligonucleotide sequences used for qRT-PCR 
gene Forward primer 5’-3’ Reverse primer 5’-3’ 
tex1 GATCAGATCTTGTAGCGGCTTATGTT
CACCAAAA 
GATCAGATCTATTTTATAAATCGAAAACAAAC
AAAAAA 
msp8 AGTGCTGTAACTTCTAATGTAGGGGA
TACAAAT 
ATCATCATCACCATTATCATCATTATCATCAC
G 
PF13_0170 TGGCTAGGATATGATTGGAAAGAACA TACGGTTCTATTTCTATATGGTGAATCA 
   
 
Table S3: alpha-helical coiled coil domains in Tex1 (P27 in bold) 
 1 
Table S3: alpha-helical coiled coil domains in Tex1 (P27 in bold) 
 
Position Sequence 
E23-L82 ELLIEYIHNLKSCLNVYRREIQEKNKYISIIKNDLSFHECILTNVNVVWSV
FNNDLLNLL 
Y477-N582 YYKNYIDIKKKISELQKDNESLKIQVDRLEKKKATLIYKLNNDNIRKHILD
NNIKDYQNGIDN 
N652- N1016 NLLKESNELYITLKEKEKENIILKNEILKMENKKDEEYEHLLNNTIEDKKE
LTRSIKELEINMMTCNMEKDKISNKVNTLEYEINVLKNIDKNQTMQLQQKE
NDILKMKLYIEKLKLSEKNLKDKIILLENEKDKMLSGIHIKDNSFNEESKS
EEGKIQLRDIQNDNDEKYDDEKKRFKELFIENQKLKEELNKKRNVEEELHS
LRKNYNIINEEIEEITKEFEKKQEQVDEMILQIKNKELELLDKFNNKMNKA
YVEEKLKELKNTYEEKMKHINNIYKKHDDFVNIYLNLFFQARKNAILSDSQ
REEQMNLFIKLKDKYDIIFQKKIELTDILKNVYDCNKKLIGHCQDLEKENS
TLQNKLSN 
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Abstract 
 
The use of synthetic peptides in vaccine development offers many advantages 
over recombinantly expressed proteins. However, the ability of short peptides to 
fold into their native structure and act as potent immunogens remains in question. 
Using a genome-wide bioinformatic approach, potential candidates were 
identified that contain alpha-helical coiled coil motif to overcome these 
impediments. The full length, hypothetical Plasmodium falciparum protein 
PFD0520c, which contains the alpha-helical coiled coil segment P90, was 
recombinantly expressed and purified. To validate the use of P90, a comparative 
analysis was performed against recPFD0520c in an antibody dependent cellular 
inhibition assay, and an enzyme-linked immunosorbent assay to determine 
antigenic recognition by adult sera from Burkina Faso. Both P90 and 
recPFD0520c showed similar effectivity in in vitro parasite killing. Antigenic 
recognition was greater for P90. Structural studies revealed that the recombinant 
protein adopted an alpha-helical conformation and formed oligomers. Low 
transcript levels of PFD0520c found throughout the intra-erythrocytic 
development cycle suggest a low abundance of PFD0520c in the blood stage. 
Indirect immunofluorescence assays were performed to determine the cellular 
localization of native PFD0520c using antibodies raised against recPFD0520 in 
mice.  An accumulation of the protein in punctuated structures within the parasite 
was detected. A tagged version of PFD0520c was recognized by the 
recPFD0520c-specific antibodies, but in Western blots performed on parasite 
lysate the same antiserum raised against recPFD0520c detected a protein at 
molecular weight twice the expected size, the nature of  which remains to be 
determined.  
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Introduction 
 
Malaria caused by the protozoan parasite Plasmodium falciparum is the most 
common and serious form of the disease, estimated to account for about 1 million 
deaths each year, the majority being young children (WHO, 2006). Efforts to 
control this devastating disease include the development of a vaccine. Obtaining 
protective immunity is a foreseeable goal and illustrated by the fact that 
individuals living in endemic areas continuously exposed to the parasite, acquire 
natural immunity over time [1,2]. 
 
Recent advances in technology and the availability of the P. falciparum genome 
have led to novel ways to rapidly identify potential vaccine candidates compared 
to traditional empirical approaches. Villard et al. (2007) took a genome-wide 
bioinformatic approach to identify potential candidates that contain an alpha-
helical coiled coil motif (CC). The rationale behind this approach is that 
candidates can be quickly identified based on the characteristic heptad repeat 
structure of the CC, in which the first and fourth residues of the heptamer are 
hydrophobic while the other residues are generally hydrophilic. Secondly, CC are 
recognized by conformational dependent antibodies. Some of these peptides 
have undergone extensive validation as malaria vaccine candidates, illustrating 
their immunogenicity [3]. Lastly, CC are, in general, stable and, when chemically 
synthesized, they readily fold in to their native structure in aqueous environment.  
 
CC segments, identified by Villard et al. (2007) are generally 30-40 amino acids 
in length and derive from proteins expressed in P. falciparum blood stages. 95 of 
these bioinformatically selected peptides were chemically synthesized and 
purified, and were subject to preclinical evaluations as vaccine candidates [3,4,5].  
 
Despite the advantages of synthetic peptides, controversy exists towards short- 
to medium-length peptides and their ability to fold into their native structure and 
act as potent immunogens. Although the approach taken by Villard et al. expects 
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to overcome these issues by synthesizing stable structures, it is of importance to 
compare the preclinical evaluations of the peptides with corresponding results 
obtained with the full length protein from which the peptide is derived. Such 
comparison will further validate the use of CC peptides in vaccinology. Here we 
further investigate the CC segment P90 deriving from the unknown predicted 
protein, PFD0520c. P90 was found to be a promising candidate in previous 
preclinical evaluation [3].  The recombinant protein and synthetic peptide are 
compared with respect to their performance in two assays: (i) an Antibody-
dependent Cellular Inhibition assay (ADCI) for demonstrating functional activity of 
anti-P90 antibodies, and (ii) Enzyme-linked Immunosorbent Assay (ELISA) for 
determining the proportion of responders to both antigens among clinically 
immune adults from a malaria endemic population. 
 
Further characterization of this vaccine candidate was undertaken, including 
investigation of structural properties of PFD0520c and P90, their ability to form a 
CC and their oligomeric state, as well as the expression profile of PFD0520c 
throughout the intra-erythrocytic development cycle (IDC) and the subcellular 
localization of the protein in infected red blood cells.  
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Methods 
 
P. falciparum culture 
P. falciparum 3D7 strain was continuously cultured with fresh human erythrocytes 
and RPMI 1640 10.44 g/l, supplemented with Hepes 5.94 g/l, Albumax II 5 g/l, 
hypoxanthine 50 mg/l, sodium bicarbonate 2.1 g/l and neomycin 100 mg/l as 
described previously [18].  
 
Preparation of recombinant His6-PFD0520c (recP)  
The ORF encoding the predicted full length sequence of PFD0520c (retrieved 
from PlasmoDB, version 5.3) was amplified from genomic P. falciparum 3D7 
DNA using primers listed in Table S1 The PCR amplified product was digested 
with NcoI and BamHI and inserted into the pQE-60 vector (Qiagen) to generate 
C-terminal His-tagged PFD0520c (His6-PFD0520c) expressing plasmid (pQE-60-
His6-PFD0520c). 
  
Expression of recombinant  His6-PFD0520c 
pQE-60-His6-PFD0520c plasmid was transformed into E. coli M15 cells 
(Qiagen).  Recombinant expression was performed following the manufacturer’s 
protocol (Qiagen Inc.). Subsequent preparation was performed using Qiagen kit 
(Qiaexpressionist) for non-native conditions. The resulting pellet containing 
insoluble proteins was resuspended in binding buffer suitable for fast protein 
liquid chromatography (FPLC) His-tag affinity purification.    
 
Recombinant protein purification 
Insoluble protein lysate was passed through a 0.45 µm filter. Purification of His6-
PFD0520c was performed by affinity chromatography using a HisTrap column 
(GE Healthcare) equilibrated with extraction buffer on a ACTA Prime Plus (GE  
 
healthcare) and the manufacturer’s pre-programmed method template named 
“on-column refold”. To remove the high salt content of the elution buffer, a further 
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FPLC purification step was performed using a HiPrep Desalting column. The 
program was input manually (15 ml equilibration step, 5 ml sample application, 5 
ml sample elution). All steps were carried out at a 1ml/min flow rate).  Exchanged 
buffers were 1 X PBS, 20 mM Tris/150 mM NaCl/0.1% Tween-20 pH 7.5, or 0.1 
M ammonium acetate pH 7.5 depending on the subsequent experiment.   
 
Determination of protein purity and identity  
To determine the purity of the protein, a Coomassie staining was performed. 
Purified protein was diluted to a 1:100 dilution before loading onto SDS-PAGE. 
His-tagged purified protein was also visualized in a Western blot using 
monoclonal mouse anti-6xHIS antibodies (1:2000, R&D Systems) and secondary 
anti-mouse IgG antibodies conjugated with horse radish peroxidase (1:20’000, 
Pierce).    
 
Peptide synthesis 
Peptides were produced by solid-phase Fmoc chemistry according to Atherton 
and Sheppard (3) and as modified by [6] using Applied Biosystems 431A and 
433A synthesizers (Foster City, CA). The final product was cleaved from p-
alkoxybenzylalcohol resin and later RP-HPLC purified. The purity was assessed 
by analytic C18 HPLC and mass spectrometry (MALDI-TOF, Applied Biosystem) 
and was found to be higher than 85%. 
 
Circular dichroism (CD) 
The CD spectra of His6-PFD0520c were recorded on a JASCO J-810 
spectrometer (JASCO corporation, Tokyo, Japan) equipped with a temperature  
controller and a 0.1 cm path length cuvette. The measurements were made in 1 
X PBS at pH 7.3 and 22°C and at a protein concentration of 0.2 mg/ml. 
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Mass Spectrometry 
Mass spectrometry was performed using Applied Biosystems Voyager-DE. 0.5 ul 
recPFD0520c in 20mM Tris-Hcl, 150 mM Nacl, 0.1% Tween, pH 7.4 buffer (0.2 
mg/ml) and 0.5 of sinapinic acid matrix solution were spotted on plate. A 
spectrum was obtained in the mass range 21 997.0 to 150 000.3. Data were 
analyzed with Data Explorer version 4.  
 
Gel filtration FPLC 
Gel filtration (Äkta FPLC, Amersham Biosciences) of 1 ml recPFD0520c 
(0.2ug/mL) in 20 mM Tris-Hcl, 150 mM Nacl, 0.1% Tween, pH 7.4 buffer was 
performed using a Superdex 200 (GE Healthcare) column following the 
manufacturer`s protocol.  
 
Affinity Purification of PFD0520c-specific antibodies from pooled sera of 
adults from Burkina Faso.  
Coupling of cyanogen bromide-activated Sepharose 4B beads (Amersham 
Biosciences) to 5 mg of recombinant protein and the isolation of specific 
antibodies was performed as described [3] using  a serum pool of adult 
individuals living in Burkina Faso.  
 
ADCI 
The inhibition of P. falciparum (3D7 strain) growth in vitro in the presence of 
human monocytes (MN) and antigen specific antibodies was carried out by the 
method described previously [7].  
 
ELISA 
ELISA’s were performed to determine recPFD0520c recognition of 39 clinically 
immune patients from Burkina Faso (BF). 96-well polysterene plates (NUNCTM   
Maxicorp cat # 468667, Nalge Nunc International Corp., Naperville, Il, USA) were 
coated with with 1 µg/ml of recPFD0520c or 5 µg/ml of peptide 90 (p90) and 
incubated overnight in a humid chamber at 4˚C. Plates were washed 4 times with 
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washing solution (1 X PBS, 0.05% Tween-20), and blocked with 1 X PBS, 0.05% 
Tween-20 containing 5% milk for 1 hour at room temperature in humid chamber. 
Sample sera were diluted 1:200 in 1 X PBS, 0.05% Tween-20, and 2.5% milk 
solution and added to the wells (50µl/well). Following 1 hr incubation at room 
temperature in humid chamber, plates were washed (as above).  Antibody-
Antigen complexes were detected by the use of goat-anti-human IgG polyvalent 
antibodies conjugated with alkaline phosphatase (Sigma Chemical Co. cat # 
A9544). The binding of goat antibodies was detected using an enzyme substrate 
buffer containing para-nitrophenol phosphate (Sigma Chemical co. cat # N-2770).  
The plates were incubated at room temperature in dark conditions for 15 minutes 
and then the reaction was stopped by the addition of 50 µl of 1 M NaOH. The 
resultant yellow colour was quantified measuring the absorbance at 405 nm.  
 
The sera from 40 Swiss, non-exposed to malaria donors were used to generate 
the cut off value for data analysis. The cut-off value was calculated using the 
equation: cut-off = (mean OD405  of Swiss donors)  +  (3*standard deviation (SD)).  
The percentage of BF adults who had a greater OD405 value compared to the cut-
off is expressed as percent recognition in (Table 1). The ratio of positive adults 
expressed as a percentage was also calculated by considering an individual 
positive if their sample OD405 was 2 times greater then the mean OD405 of the 
non-exposed controls. 
  
Immunogenicity in mice  
Two inbred strains of mice were injected with 20 µg of antigen formulated in 
Montanide ISA 720 (35 µg/ mouse), alum or EM005 [8]. Each mouse was 
injected either subcutaneously at baseline  of the tail (Montanide, 50 µl/ mouse or 
EM005 100 µl/ mouse) or intraperitoneally (Alum, 500 µl/ mouse) at 0, 3 and 8 
weeks. The induced antibody responses were assessed by ELISA 10 days 
following second and third immunizations.  
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RNA isolation, cDNA synthesis and real time PCR 
3D7-infected erythrocytes were tightly synchronized to a theoretical time frame of 
2 hours and grown to 8-10% parasitemia (5% heamatocrit). 1.5 ml culture was 
taken in 4h intervals. In brief, parasite RNA was extracted using TRIzol 
(invitrogen) according to the manufacturer’s instructions. TRIzol extraction was 
repeated. Residual gDNA was digested twice with RQ1 DNase (Promega) 
according to the manufacturer’s protocol. Reverse transcription was done by 
AffinityScript Multiple Temperature Reverse Transcriptase (Stratagene) with 
random primers (Invitrogen) as described by the manufacturer. To control for 
gDNA contamination, the target sequence was amplified from the RNA solution 
prior to reverse transcription. The primers used for qPCR of PFD0520c, 
PF13_0170 and msp8 are shown in supplementary material Table S1. Absolute 
transcript quantification was performed at a final primer concentrations of 0.4mM 
using SYBR® Green Master Mix (Applied Biosystems) on a StepOnePlusTM Real-
Time PCR System (Applied Biosystems) in a reaction volume of 12 µl. All 
reactions were performed in triplicate yielding virtually identical Ct values. A serial 
dilution of gDNA was used as standard for absolute quantification. Relative 
transcript profiles were calculated by normalization against transcript levels of the 
house-keeping gene PF13_0170 (glutaminyl-tRNA synthetase). 
 
Plasmid construct and parasite transfection 
The PFD0520c ORF was amplified from 3D7 genomic DNA using the primers 
listed in Table S1. The fragment was cloned into the pBcam-3xHA vector [9] via 
the BamHI and NheI restriction sites. Transfections were performed as described 
in [10] and selected on 5µg/ml blasticidin-S-HCl. 
 
Indirect Immunofluorescence Assay (IFA). 
Infected erythrocytes were fixed, permeabilized and blocked as described [11]. 
Primary antibodies were used with the following concentrations: polyclonal rabbit 
sera anti-SERP (1:400); polyclonal mouse antibodies anti-recPFD0520c (1:500); 
anti-mpPFD0520c (1:500); monoclonal anti-rat antibodies: anti-HA (Roche 
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Diagnostics, 1:200). Secondary antibodies used: anti-rabbit IgG (Alexa Fluor 488, 
Invitrogen; 1:400); anti-mouse-IgG (Texas Red, Invitrogen; 1:400) and anti-rat 
IgG (Alexa-Fluor® 568 Molecular Probes, 1:400). Cells were mounted in 
Vectashield Hard Set supplemented with DAPI (Vector Laboratories) for staining 
of the nuclear DNA. Images were obtained by the Zeiss confocal microscope 
LSM 700. Images were processed by ImageJ software or the Huygens Essential 
Software (Scientific Volume Imaging, The Netherlands). 
 
Lysate preperation and Western Blot  
To obtain protein extract of mixed stage infected erythrocytes, 10 ml of 3D7 
parasite culture   was grown in a petri-dish to 5% to 10% parasitemia, lysed on 
ice in 0.03% saponin in phosphate-buffered saline (PBS, pH 7.4) for 10 min, 
washed with ice-cold PBS for complete removal of haemoglobin, and 
resuspended in Laemmli sample buffer. 
 
For Western blot analysis protein extracts were separated on a 12.5% sodium 
dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose (Hybond-C 
extra; GE Healthcare) at 4°C for 1 h at 80 V and an additional hour at 100 V. The 
membrane was blocked for 1 h in 5% skim milk, 0.1% Tween in Tris-buffer. The 
following antibodies were used: polyclonal mouse sera: anti-recPFD0520c  
(raised in C3H mice, 1:2000); anti-recPFD0520c (raised in CB6F1 mice, 1:2000); 
anti-mpPFD0520c; (1:2000); anti-p90 (1:200); monoclonal anti-rat antibodies: 
anti-HA (Roche Diagnostics, 1:500); horseradish peroxidase-conjugated goat 
anti-mouse (Pierce, 1:20 000), goat anti-rat (Acris, 1:5000). 
 
Two-dimensional gel electrophoresis (2-DE) 
Protein extraction was done using 50 ml of mixed stage infected erythrocytes 
grown to 5% parasitemia. Cells were lysed on ice in 0.03% saponin in 
phosphate-buffered saline (PBS, pH 7.4) for 10 min, washed with ice-cold PBS 
for complete removel of haemoglobin and further extracted by 
methanol/chloroform.  
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Isoelectric focusing (IEF) was carried out in 7 cm IPG strips (ReadyStripTM, Bio-
Rad) with nonlinear pH gradient of 3-10. The process was performed using 
Protean® IEF System (Bio-Rad) with a surface temperature of 20°C and a 
maximum current of 50 µA/strip. Protein pellet was reconstructed in sample 
buffer (7M urea, 2M thiourea, 4% CHAPS, 5mM TBP, 0.25% SDS, 2% Biolyte). 
An aliquot containing 100 µg of protein was mixed with appropriate amount of 
rehydration buffer (8M urea, 1% CHAPS, 2mM TBP, 0. 25% Biolyte) so that 130 
µl of sample were applied to the IPG strip by in-gel rehydration at 20°C for 12h. 
After the rehydration step the IEF was run for a total of 62 250 Vh. Following the 
IEF, the strip was reduced in equilibration buffer (6M urea, 30% glycerol, 5% 
SDS, 0.05 M Tris, pH 8.8) containing 1% DTT for 10 minutes and then alkylated 
in equilibration buffer containing 5% iodoacetamide for 10 minutes. The second 
dimension was performed on a 12% SDS-polyacrylamide gel. Western blot was 
performed as described above. 
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Results 
 
The predicted coding sequence for PFD0520c spans nucleotide positions 
482’841 to 483’482 on chromosome 4. According to PlasmoDB version 6.5 
(http://plasmodb.org), the PFD0520c has a length of 213 amino acids (aa) and a 
predicted molecular weight of 25 377 Da. PFD0520c contains 1 predicted coiled 
coil domain (P90) encompassing region from T61 to V98. On protein sequence 
level P90 was found completely conserved in 14 different culture strains and in 
malaria positive field samples from Tanzania and Papua New Guinea. One 
synonymous SNP was detected at nucleotide position 195 (T to C) in 1/14 culture 
strains and in 4/23 samples from Papua New Guinea [5]. 
 
Recombinant PFD0520c (recPFD0520c) expression  and purification 
The molecular weight of the recombinantly expressed PFD0520c with the 
additional 6xHIS tag was calculated to be 26 433 Da. The protein was 
successfully expressed in E.coli from which it was retrieved predominantly as 
insoluble protein (Figure 1A/1B). RecPFD0520c was purified from the insoluble 
protein fraction using FPLC (Figure 1C). The purity of the protein was confirmed 
with mass spectrometry (MS, data not shown). CD data indicate the presence of 
alpha-helical structures in the recombinant protein (Figure 1D). 
   
Specificity of polyclonal antibodies raised in mice against recPFD0520c 
Polyclonal antibodies purified from C3H and CB6F1 mice strain immunized with 
recPFD0520c were analysed in Western blot to confirm recombinant protein 
recognition. The recombinantly expressed protein was recognized by the 
polyclonal mouse sera. At a dilution of 1:10’000, a clean and sharp band was 
obtained at the expected protein MW (Figure 2).  
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ADCI assay results using human purified anti-recPFD0520c antibodies were 
comparable to those using human purified anti-P90. 
The antibody-dependent cellular inhibition assay investigates the function of 
antibodies for in vitro parasite killing in the presence of monocytes [7,12]. Purified 
IgG from semi-immune adults was shown to inhibit parasite growth in vitro in 
cooperation with monocytes [7].  When using human purified antibodies against 
recPFD0520c a specific growth index (SGI) of 75% was measured. Two 
independent ADCI assays were performed using human purified antibodies 
against P90 and the SGI values were 70% and 43%.  
  
Adult immune  sera showed similar recognition of P90 and overlapping 
protein fragments compared to recPf90. 
The sera from 39 clinically immune adults from Burkina Faso were tested in 
ELISA for reactivity with recPFD0520c and P90 (Table 1). The percent 
recognition of sera tested was 59% and 43% for p90 and recPFD0520c 
respectively.  The percentage of positive individuals when a secondary method of 
determining reactivity based on ratio is used was 41% for both antigens. 
 
PFD0520c was expressed in intraerythrocytic blood stage parasites but at 
very low level 
The transcription profile was analyzed by RNA isolation and quantification of 
reverse transcribed cDNA from tightly synchronized cultures harvested in 4 h 
intervals covering the 48h intra-erythrocytic development cycle. In these 
experiments the developmental stage of synchronized parasites of each time 
point were expected not to vary for more than 2 h. The transcript abundance was 
quantified by gRT-PCR at all time points. The transcription level of PFD0520c 
was normalized to a constitutive transcribed gene, glutaminyl-tRNA synthetase 
(PF13_0170). PFD0520c-specific transcripts were detected throughout the intra-
erythrocytic development cycle, however, the transcript abundance was very low  
(Figure 4). The low level of PFD0520c expression in blood stage parasite was in 
agreement with the expression data available at PlasmoDB. To validate the 
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synchronization procedure, transcript levels of the merozoite surface protein 8 
(msp8) were analyzed at each time point. The msp8 profile obtained was in good 
agreement with the previously shown up-regulation of msp8 in ring stages and in 
very late schizont stages (data retrieved from PlasmoDB, http://plasmodb.org). 
 
Polyclonal mouse sera did not recognize the endogenous protein at the 
expected MW in parasite lysate  
Anti-recPF0520c specific polyclonal mouse sera raised in C3H and CB6F1 mice 
were used to characterize by Western Blot the native protein from 3D7 parasite 
lysate. Both mouse sera recognized a single band of the approximate molecular 
weight of 50 kDa (Figure 5A). However, the predicted molecular weight of 
PFD0520c is 25 377 Da (PlasmoDB). In order to analyze PFD0520c migration 
and possible protein dimerization, a transgenic parasite line was generated that 
expressed the predicted full-length PFD0520c protein fused to a Hemagglutinin 
Tag (HA-tag). HA-specific antibodies as well as the recPFD0520c-specific 
polyclonal mouse sera detected the HA-tagged version at the expected MW of 
around 30 kDa (Figure 5A and 5B). Dimer formation of the HA-tagged protein 
was not detected (Figure 5A and 5B). Migration of the HA-tagged version did not 
differ between reduced versus non-reduced condition for the protein lysate of the 
transgenic parasite line (Figure 5A and 5B).  
 
The entire predicted PFD0520c protein had previously been synthesized as five 
overlapping peptide fragments (Figure 6). Mouse serum was generated against 
this peptide mixture (anti-mpPFD0520c). Equally to the anti-recPFD0520c mouse 
sera, the anti-mpPFD0520c sera recognized the HA-tagged version and the 50 
kDa protein (Figure 5B). Sera raised against P90 failed to detect the HA-tagged 
protein or additional bands (Figure 5B). 
 
PFD0520c localized to punctuated structure within the parasite 
To study the subcellular localization of PFD0520c, infected RBCs were analyzed 
by immunofluorescence analysis (IFA). The endogenous protein was detected in 
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punctuated structures within the parasite (Figure 7). The parasite boundary is 
illustrated by staining of the parasitophorous vacuole (PV) by polyclonal rabbit 
sera specific for SERP (serine-rich protein/antigen 5). SERP was shown to be 
exported and to accumulate in the PV until parasite egress [13]. To compare the 
localization pattern of the native protein with the HA-tagged PFD0520c version, 
the transgenic parasite line was analyzed in IFA. HA-tag specific antibody 
detected the fusion protein at similar punctuated structure within the parasite 
(Figure 7). 
 
Proteomic analysis of parasite lysate 
To determine whether the recPFD0520c-specific mouse serum  cross-reacted 
with a protein of an approximate size of  50 kDa 3D7 lysate of mixed parasite 
stages was separated in two dimensions (Figure 8A). A single signal was 
obtained after Western blot of the 2D gel with recPFD0520c polyclonal mouse 
antibody. 
 
 
Discussion 
 
RecPFD0520c was successfully expressed. Western blots analysis suggest that 
contaminant proteins were still present in the purified protein solution. Polyclonal 
mouse recPFD0520c-specific antibodies indeed recognized the recombinant 
protein, but also additional bands both below and above the expected weight of 
recPFD0520c appeared when a higher antibody concentration was used. These 
additional bands, however, were not recognized with anti-HIS monoclonal 
antibodies and therefore it was concluded that contaminant proteins were present 
in the purified protein solution.  
 
In order to investigate the structural properties of recPFD0520c a CD spectra 
was obtained. The protein’s secondary structure is, in part, alpha helical. 
Reference spectra are available from a set of CD spectra with known secondary 
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structure determined by x-ray crystallography [14]. The consensus reference CD 
spectra for an α-helix consists of a positive peak at about 190-195 nm with a 
magnitude of about 60 000-80 000 deg cm2/decimole, and two negative peaks at 
207 nm and 222 nm with a magnitude of around -36 000 + 3 000 deg 
cm2/decimole at 222 nm [14]. Comparison of the standard α-helix spectra with 
that of recPFD0520c confirmed that all characteristic peaks occur at the same 
wavelengths. The magnitude of the 222 nm peak of recPFD0520c protein is 
above 50% of the reference value, indicating that the purified full-length 
recPFD0520c protein exhibits an alpha-helical content of at least 50%. 
 
Purified recPFD0520c protein was analyzed by gel filtration. The peak height 
represents the protein concentration. For RecPFD0520c three protein elution 
peaks were observed, with increasing peak heights and thus lower concentration 
for the highmolecular elution peaks and higher concentration of the low molecular 
weight (monomeric) peak. (Figure S1). This suggested that the recPFD0520c 
protein solution contained monomers, dimers, and trimers of the full length 
protein.  
 
Further indication of recPFD0520c dimer formation was provided by SDS page 
followed by Coomassie staining of unreduced and reduced conditions. The 
strong band at the expected MW of the protein (27 kDa) represents the 
monomer. An additional band of about 54 kDa representing the dimer was 
detected (Figure S2). Difference in band intensity suggested that the monomeric 
form was more abundant and dimer formation could be completely resolved in 
reducing conditions.   
 
MS analysis also infers the presence of monomers, dimers and to a slight extent 
trimers due to the peaks found at approximately each expected oligomeric 
molecular weight.  Discrepancies were found between the molecular weight of 
the monomeric form of recPFD0520c calculated from the sequence data (26 443 
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Da) and that calculated by MS (26 746 Da) (data not shown). This discrepancy 
remains to be resolved by recalculation and repeating the MS experiments. 
  
The results of the ADCI assay performed with human purified antibodies, specific 
to recPFD0520c and P90, suggested that these antibodies cooperated with 
human monocytes to inhibit malaria erythrocytic growth in vitro. The SGI values 
obtained for purified human-recPFD0520c antibodies were comparable to the 
P90-specific human antibodies with SGIs of 75% and 45, 73% respectively. The 
structural analysis of recPFD0520c suggested that the CC region was correctly 
folded. However no structural information is available from the remaining parts of 
the protein and if the recPFD0520c mimics entirely the parent protein remains 
unknown. The slightly increased effect measured for the recPFD0520c-specific 
antibodies in ADCI might indicate that additional epitopes are recognized by 
these antibodies. However, there is the possibility of protein-unrelated antibodies 
due to the presence of E. coli proteins in the recPFD0520c preparation resulted 
in an increased effect measured by ADCI.  
 
ELISA results demonstrated a good recognition of the coiled coil fragment P90 by 
59% of hyperimmune sera tested. In contrast, only 43% of these sera gave 
positive results for recPFD0520c.  Insufficient recombinant protein purification 
might explain these differences. This highlights one of the greatest advantages of 
chemical peptide synthesis. The background in ELISA assays is considerably 
reduced using pure synthetic peptide.  As negative controls were the same in 
both experiments, the cut off calculated for plates coated in P90 was much lower 
than that for the recombinant protein. This led to a higher number of responders 
for P90. It is unlikely that differences in coating concentration would account for 
the observed discrepancy.  The concentration of P90 used was 5µg/ml, and the 
concentration of recPFD0520 was 1 µg/ml. However, when an ELISA was 
repeated using 5 µg/ml of recPFD0520c, the same results were observed.  
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The impurities present likely consist of E. coli proteins not removed during the 
purification process. Humans are confronted constantly with E. coli antigens as 
E. coli is a natural symbiont of the intestinal tract. Humans likely mount humoral 
responses against E. coli proteins that could interfere with serological testing.  
Another factor may be a greater representation of conformational epitopes 
associated with the CC structure in the P90 ELISA. In the absence of other 
competing epitopes on the plate surfaces coated, the CC fragments might reach 
an optimal packaging concentration.   
 
Mouse sera detected a protein at 50 kDa. We initially hypothesized that the shift 
of molecular weight was due to strong dimer formation also observed for the 
recombinant protein expressed in E. coli .To test this hypothesis we generated a 
transgenic parasite line expressing PFD0520c fused to an HA-tag. The Western 
blot analysis on transgenic lines did not confirm our hypothesis of dimer 
formation. In reduced and non-reduced condition the HA-tagged PFD0520c 
protein was detected as monomer. The HA-fusion protein might be prevented 
from adopting dimer conformation due to steric hindrance caused by the HA-tag. 
Moreover, the possibility exists that the endogenous protein contains 
modifications favouring dimer formation or constituting other causes for the 
observed shift in migration.  
 
Alternatively, the mouse sera could cross-react with another protein expressed in 
blood stages. Expression profile revealed that PFD0520c is expressed at low 
level. Detection of low abundant proteins by Western blot is difficult. This open 
question could be addressed by MS analysis to identify the protein content of the 
single spot in the 2D gel that was detected by the polyclonal mouse sera.  
 
Subcellular localization of PFD0520c using different mouse sera and the 
localization of the HA-tagged version revealed similar localization pattern. The 
protein accumulated in punctuated structures within the parasite. However, 
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further co-localization experiments are needed to determine the identity of these 
structures. 
 
Conclusion  
 
The goal of this study was the comparative analysis of the synthetically produced 
P90 and the recombinantly expressed PFD0520c, in order to validate the 
continued development of P90 towards a long synthetic peptide based malaria 
vaccine. All comparisons performed indicated similar performance of both 
antigens. The two most important parameters relevant for evaluation of vaccine 
candidates are reactivity with sera from endemic areas, and a high SGI value in 
the functional assay. Both criteria were met equally well by the synthetic peptide 
and by the purified recombinant protein.  
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Tables 
 
Table 1: Summary of ELISA results of BF clinically immune individual’s 
recognition of P90 and recPFD0520c. 
 
Peptide/Protein MW (Da) % 
recognition 
Ratio 
(%) 
Mean 
OD405 
Cut 
off  
P90 4 475 59 41 0.401 0.140 
recPFD0520c 26 443 43 41 0.257 0.218 
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Figures 
 
 
 
Figure 1: Expression, purification and structural analysis of recPFD0520c. 
Coomasie gel of E. coli protein extracts of parallel 25 ml cultures (A & B) of M15 
cells containing pQE-60 with PFD0520c insert. Protein extract of uninduced 
culture (-IPTG) and induced culture (+IPTG). Soluble protein fraction after E. coli 
lysis and insoluble protein fraction after lysis. Western blot analysis of the same 
fractions. Antibody used for recPFD0520c detection: mouse monoclonal 
antibody: anti-6xHis (R&D Systems). Positive control recDHFR fused to 6xHis-
tag (pos). 
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Figure 2: recPFD0520c-specific mouse recognized recPFD0520c. Sera 
raised against recPFD0520c in C3H mice (left) and in CB6F1 mice (right) 
recognize the recombinant protein. Different dilution of the polyclonal mouse 
antibodies were used (1:1000; 1:5000; 1:10’000). The pre-immune of both mice 
did not recognize the recombinant protein. 
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Human purified antibody recognition of recPFD0520c from Burkino 
Faso semi-immune sera pool 
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Figure 3: anti-recPFD0520c affinity purified antibodies from a pool of adult 
sera from Burkina Faso.   
T- stands for negative test sera from a Swiss donor, non-exposed to malaria 
(negative control); Bef col (before purification, dark blue graph); Aft col (after 
purification, pink squared graph) 
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Figure 4: Abundance of PFD0520c transcripts by gRT-PCR. RNA was 
isolated from tightly synchronized culture in a 4h interval. Transcript levels were 
normalized to the transcript abundance of the constitutively expressed 
glutaminyl-tRNA synthetase (PF13_0170). As a control for complete 
synchronization msp8 transcripts were measured and compared to the 
PF13_0170 transcript level (green curve) 
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Figure 5: Serum specificity tested on parasite lysate by Western blot. 
Protein lysate of mixed stage 3D7 parasites (3D7) and protein lysate of the 
transgenic parasite line (Tg) expressing the PFD0520c fused to HA-tag was 
separate by SDS-PAGE. Tg lysate was either reduced (Tg red) or non-reduced 
(Tg non-red).  
 
 
 
 
 
Figure 6: Predicted PFD0520c protein sequence. The localization of synthetic 
peptides (P1, P2, P3, P4, P5) within the protein are indicated with coloured bars. 
P90, the coiled coil region of PFD0520c is highlighted in grey. 
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Figure 7: Localization of PFD0520c in late stage parasites. Anti-
recPFD0520c-specific polyclonal mouse sera (A, in red) or anti-mpPFD0520c 
polyclonal mouse sera (B, in red) was used to detect endogenous PFD0520c in 
fixed 3D7 infected RBC. PV staining was obtained by SERP-specific polyclonal 
rabbit sera (in green). Anti-HA antibodies were used to detect the HA-tagged 
PFD0520c in transgenic cells (C, in red). Scatter plots show the result of the co-
localization of the PFD0520c and SERP signal. Nuclear DNA was stained with 
DAPI (blue), Transmission image (DIC), scale bar: 5 mm. 
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Figure 8: 2D separation and protein for protein identification by mass 
spectrometry. Mixed stage 3D7 parasite lysate was separated in two 
dimensions. recPFD0520c-specific polyclonal mouse sera (CB6F1 mice) was 
used to detect the supposed endogenous PFD0520c protein (B, black arrow). 
This area was cut out of the protein gel (C, black arrow). 
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Supplementary material 
 
Table S1: Oligonucleotide sequences used for cloning (restriction sites in 
bold) or qRT-PCR 
 
Primers for cloning HA-tagged fusion protein 
Fragment Forward primer 5’-3’ Reverse primer 5’-3’ 
PFD0520c GCGTGGATCCCCATGAGACATAAAATTT
CCG 
GCGTCCATGGATATTGGAAGCGCGCTTATCA  
   
Primers for cloning E. coli expression construct 
 GCGTCCATGGCCATGAGACATAAAATTT
CCG 
GTCGAGATCTATATTGGAAGCGCGCTTATCA 
   
Primers for qRT-PCR 
PFD0520c GACGCCTCCGCCTGTATGAATAAT CTTGAGCTTTAGAAATTCGTACTTTGTT 
 
Msp8 AGTGCTGTAACTTCTAATGTAGGGGATAC
AAAT 
ATCATCATCACCATTATCATCATTATCATCAC
G 
PF13_0170 TGGCTAGGATATGATTGGAAAGAACA TACGGTTCTATTTCTATATGGTGAATCA 
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Gel filtration of recPFD0520c
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Figure S1: Gel filtration chromatography elution profile of recPFD0520c. 
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Figure S2: Dimer formation of recPFD0520c in non-reducing conditions. Non-red 
(non-reduced), dimer band indicated with a black arrow. Reduced conditions: 
addition of β-mercaptoethanol (red-bmETOH) and DTT (red-DTT). 
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General discussion 
 
The importance of research for vaccines development against malaria cannot be 
overstated. Today’s most advanced vaccine formulation against malaria is 
RTS,S/AS01. This vaccine targets the pre-erythrocytic parasite stage but has 
shown to provide only 30-66% protection against clinical episodes [1]. The new 
generation malaria vaccine should provide at least 80% protection. This might be 
only achieved by targeting all stages of the parasite. To target the blood stage of 
parasite is essential because this stage is associated with all the symptoms of 
the disease. In contrast to the pre-erythrocytic vaccines, vaccines targeting the 
parasite blood stage could without showing 100% efficacy provide reliable 
protection against severe disease.  
 
Children from malaria endemic regions develop immunity against severe disease 
quite rapidly, in general already after the first or the second infection [2]. Under 
constant exposure individuals develop clinical immunity. The mechanisms that 
underlie this immunity remains only poorly understood but antibodies were 
demonstrated to play a critical role in controlling blood stage infection. The 
transfer of purified IgG from malaria-immune adults to children suffering from 
high parasitemia and severe symptoms were shown to rapidly reduce 
parasitemia and symptoms [3]. Maternal antibodies are among the factors 
protecting infants in their first few month of life against [2] providing another 
evidence for the central role of antibodies in malaria immunity. However, which 
proteins elicit the production of protective antibodies and what is the nature of the 
antibody effector function remains unclear.  
 
The availability of the P. falciparum genome [4] has opened the path to 
identifying, evaluating and characterizing new targets for malaria vaccine 
development. The P. falciparum genome encodes for 5400 putative proteins the 
majority of which is uncharacterized and therefore annotated as hypothetical 
proteins. The expression profile of these proteins varies due to the complex 
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multi-stage life cycle of this parasite. Despite the completion of the genomic 
sequence of P. falciparum [4] and availability of the protein expression data 
[5,6,7], vaccine development has focused only on 0.5% of all proteins of the 
entire P. falciparum proteome [8].  
 
The approach described in this thesis was based on genome-wide screens for 
alpha-helical coiled coil domains present in proteins expressed in the blood stage 
of the parasite. Villard and coworkers predicted 166 coiled coil domains in 131 
blood stage expressed proteins [9]. Analysis of the transcriptome of the complete 
blood stage cycle revealed that at least 60% of the genome is transcriptionally 
active during this stage [10,11,12]. This corresponds to 3240 expressed proteins. 
Our selection therefore represents 4% of the proteome expressed in the blood 
stage. 
 
The rationale behind choosing this structural motif was that (1) candidates can be 
quickly predicted based on the characteristic heptad repeat structure of the 
alpha-helical coiled coil motif; (2) alpha-helical coiled coil motifs are recognized 
by conformational-dependent antibodies; (3) alpha-helical coiled coils are stable 
and, when chemically synthesized, peptides with this motif readily fold into their 
native structure; (4) synthetic peptides are advantageous over recombinantly 
expressed proteins in that no expression or elaborate purification system is 
required, making the vaccine development process much less time consuming. 
 
Alpha-helical coiled coils are highly abundant structural protein motifs [13]. Coiled 
coil domains mediate oligomerization and were found to be a requirement for the 
biological function of many investigated proteins [14,15,16]. In the ring exported 
protein 1 (Rex1) the coiled coil domain was found to be crucial for the association 
to MC [17]. This led us to hypothesize that these motifs might exhibit very limited 
sequence diversity. We therefore studied sequence conservation of alpha-helical 
coiled coil domains present in P. falciparum proteins and found a high degree of 
conservation of this structural motif. In culture strains only 3 out of 14 alpha-
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helical coiled coils showed point mutations and/or length polymorphisms. In field 
isolates 3 out of 5 investigated peptides were completely conserved. All 166 
putative alpha-helical coiled coil domains, which had been originally identified in 
the P. falciparum genome by the bioinformatics selection procedure described by 
Villard and coworkers (2007), were analyzed in silico for the presence of singles 
nucleotide polymorphism. By querying the SNP data base at PlasmoDB, which 
contains the genomes of 15 different isolates, we revealed that 82% (137/166) of 
these peptides were conserved. This important finding supports the choice of the 
coiled coil structural motif for vaccine development because such an immunogen 
should ideally be derived from conserved epitopes. This represents a potential 
advantage in vaccine development since extensive polymorphism had previously 
posed a major obstacle. 
 
Polymorphic epitopes may divert the effective response. Detailed investigations 
of blood stage antigens revealed that the polymorphic regions are generally 
immunodominant [18,19,20]. There is evidence that naturally exposed individuals 
develop both, strain-specific immune responses as well as cross-reactive 
responses recognizing a broad array of P. falciparum strains [2]. However, it 
remains unknown whether the antibodies against polymorphic regions or those 
against conserved regions are more relevant for protection. Conserved regions 
were found to be less antigenic and immunogenic than polymorphic regions 
[19,20,21,22]. In contrast to these observations we showed that the majority of 
our candidates were both conserved [23] and antigenic [9]. Constraints on the 
secondary structure of coiled coils likely contribute to sequence conservation.   
Peptide recognition by semi-immune adults from different endemic areas was 
initially studied by ELISA in order to demonstrate antigenicity of these fragments 
in humans [9]. However, a high prevalence of responders is no evidence of a B-
cell mediated protective response. There is no direct link between antibody 
recognition and protection in the absence of further functional information. 
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In vitro assays that correlate with in vivo protection would facilitate the selection 
of effective vaccine candidates. In vitro growth inhibition assay measures the 
function of antibodies to block RBC invasion and/or intra-RBC growth. Purified 
IgG from semi-immune adults was shown to inhibit parasite growth in vitro. A 
positive correlation was found between high degree of growth-inhibitory activity of 
sera collected prior to the rainy season and a decreased probability of 
experiencing clinical malaria during malaria season [24]. However, there were 
also individuals with a relatively high level of growth-inhibitory activity who got 
malaria and individuals with a relatively low level who did not get malaria [24]. 
This suggests that antibodies that block merozoite invasion or and/or inhibit 
parasite growth may contribute, but are not sufficient for protection. The primary 
method for measuring antibody-mediated effector function in the course of the 
current collaborative project, as well as for selecting the candidates investigated 
in this PhD thesis, was the antibody-mediated cellular inhibition assay (ADCI) 
[25,26,27,28]. This assay investigates the function of peptide-specific antibodies 
for in vitro parasite killing in the presence of monocytes. Monocytes are activated 
when two distinct Fcγ-receptors are simultaneously engaged by a minimum of 
two cytophilic IgG molecules bound to an antigen containing at least two B cell 
epitopes [27]. However, it remains to be determined whether the extent of in vitro 
parasite killing by ADCI can serve as correlate for protection. This assay 
depends on the use of fresh monocytes and is therefore difficult to standardize. 
There are efforts to adapt this assay using a monocyte-like cell line. However, 
these efforts have so far been unsuccessful, possibly due the lack of the full 
complement of human Fc-receptors that are essential for mediating immunity 
[29]. Taken into account that various antibody-mediated effector functions 
(blocking of cytoadherence, opsonization and destruction of free merozoites and 
iRBC by phagocytic cells, neutralization of toxic molecules and ADCI) could be 
involved in protection seen in semi-immune individuals, it seems unlikely that a 
single assay measuring one specific effector function could predict reliably in vivo 
protection. 
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In recent years peptides exposing stable structures including alpha-helical coiled 
coil motif and intrinsically unstructured regions (IUR) were increasingly used for 
vaccine development [30]. The skepticism towards synthetic peptides for vaccine 
or drug development has almost vanished due to many successful vaccine 
developments in the fields of cancer or against allergies [30]. IURs are highly 
abundant in the P. falciparum genome and are present in approximately 40 % of 
all proteins [31]. These segments are longer than 50 aa. It would be promising to 
evaluate them for vaccine potential because they may contain more epitopes 
than the our selected alpha-helical coiled coil segments. The IUR of Tex1 
(PFF0165c) was investigated in more detail [32]. The principal findings that P27A 
contains multiple T- cell and B-cell epitopes, is recognized by sera of a majority of 
naturally exposed individuals, is highly immunogenic with different adjuvants, is 
well conserved and that P27A-specific human and mouse sera inhibit parasite 
growth in vitro support further preclinical and clinical development of P27A. A 
phase I clinical trial was approved by the European Malaria Vaccine Initiative 
(EMVI) and currently the GLP-grade immunogen production is ongoing. 
 
Interestingly, a sequence analysis of the Tex1 orthologues in P. vivax 
(PVX_113335) and other Plasmodium species (P. knowlesi (PKH_114650), P. 
berghei (PB001170.02.0), P. chabaudi (PCAS_010290), and P. yoelii (PY02581)) 
revealed that the IUP region as well as the signal sequence is exclusively 
present in P. falciparum Tex1. We showed that the P. falciparum Tex1 
expression was upregulated in early trophozoites. However, the P. vivax 
orthologues is expressed mostly in ring stage parasites (PlasmoDB). 
Transcriptome analysis of P. falciparum and P. vivax throughout the RBC cycle 
revealed that 11% of the syntenic genes show dramatically altered expression 
between the two species [33]. For many proteins diversion of the amino acid 
sequence is coupled with alteration of the transcriptional profile. This may reflect 
functional evolution of these proteins between the two Plasmodium species. 
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In the traditional approach of considering only surface-located antigens as 
potential vaccines, it was assumed that blocking antibodies were elicited.  The 
detailed analysis of Tex1 subcellular localization revealed no surface exposure. 
The protein was exported in trophozoites and associates to MC membrane facing 
the RBC cytosol. In late schizont Tex1 was found in very close proximity to the 
RBC membrane, probably still associated to MC. To determine the exact 
localization of Tex1 in this stage would go beyond the resolution of fluorescence 
microscopy, and would require electron microscopy images. Both P27A-specific 
as well as P27-specific antibodies did not detect Tex1 at the surface of 
unpermeabilized late schizont stage-infected RBCs. Upon parasite rupture, Tex1 
is freed and exposed to the human immune system. Antibody-mediated effector 
mechanisms providing protection via Tex1-specific antibodies therefore exclude 
processes like invasion inhibition or blocking of cytoadherence. Previously it was 
shown that soluble antigens are just as efficient to triggering ADCI as antigens 
present at the merozoite surface [27]. This indicates that antigens released upon 
schizont rupture as well as antigens released by lyzed parasites are capable of 
inducing in vitro parasite killing in combination with monocytes. The previous 
work of our collaborators showed that P27A- and P27 specific human antibodies 
were equally effective in triggering ADCI as a pool of purified IgG from semi-
immune adults [9,32]. we have additionally shown that this effect of in vitro 
parasite killing can be induced also by P27A-specific mouse serum [32]. 
Intracellular proteins of other parasites have been shown to induce protective 
antibodies. For example, immunization with heavy chain Brugia malayi myosin 
induced protection after challenge in rodent models [34]. It is therefore not 
justified to dismiss immunogenic proteins categorically as potential vaccine 
targets based solely on their lack of surface exposure. 
 
This thesis contributed to the characterization of novel blood stage vaccine 
candidates that were identified by bioinformatic tools and high through-put 
peptide synthesis followed by stringent experimental selection. The results of this 
thesis provide evidence that the approach initiated by our collaborators indeed is 
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valuable. Provided the outcome of clinical trials further supports this strategy, the 
same approach could be applied for vaccine development against many other 
pathogens from which genome data is available.   
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Appendix 
Table 1: Sequences and Nomenclature of peptides (1 to 95) used in the study.  
 
Peptides 
 
Proteins 
 
 
Sequences (Plasmodb.org) 
1 PFA0170c 
 
(VNNLDSTVNYMNSTGNNINNI)3 
2 PFB0145c 
 
TISSLSNKIVNYESKIEELEKELKEVK 
3 NIKTMNTQISTLKNDVHLLNEQIDKLN 
4 EIEKLNKQLTKCNKQIDELNEEVEKLN 
5 IIDIKKHLEKLKIEIKEKKEDLENL 
6 INNLNEKLEETNKEYTNLQNNYTNE 
7 IDKLNNEKGTLNSKISELNVQIMDL 
8 IKTMNTQISTLKNDVHLLNEQIDKLNNEKGTLNSKISELNVQIMDL 
9 LLSKDKEIEEKNKKIKELNNDIKKL 
10 LNLVDQGKKKLKKDVEKQKKEIEKL 
11 ICSLTTEVMELNNKKNELIEENNKLNLVDQGKKKLKKDVEKQKKEIEKL 
12 PFB0145c VDKIEEHILDYDEEINKSRSNLFQLKNEICSLTTEVMELNNKKNELIEENN
KLNLVDQGKKKLKKDVEKQKKEIEKL 
13 LDENEDNIKKMKSKIDDMEKEIKYR 
14 PFC0245c GMNNMNGDINNIN(GDINNMN)4 
15 PFD0110w LIKYMNERYQNMQQGYNNLTNYINQYE 
16 DINSTNNNLDNMLSEINSIQNNIHTYI 
17 EKKLDILKVNISNINNSLDKLK 
18 DVHNIKEDYNLLQQYLNYMKNEMEQLK 
19 DEKINDYLEEIKNEQNKIDKTIDDI 
20 MDVVINQLRDIDRQMLDLYKELDEK 
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21 ISNIFKDIQNIKKQSQDIITNMNDM 
22 LEEIIKNLDILDEQIMTYHNSIDEL 
23 FQKVKEKAEIQKENIEKIKQEINTL 
24 EKKLDILKVNISNINNSLDKLKKYYEEALFQKVKEKAEIQKENIEKIKQEINT
L 
25 PFD1115c D(VTHLTND)4VTHLT 
26 PFE0570w NLNKVKININDLNNNIVDVNNSIHNIE 
27 PFF0165c 
 
KKRNVEEELHSLRKNYNIINEEIEEIT 
28 YIDIKKKISELQKDNESLKIQVDRL 
29 MAL7P1.162 QMEGFQKQLDRLSDSLSKIQKALGEYL 
30 PF11_0213 LKLNEGLENIKQELHIIDRELKNIL 
31 PFL1135c NINSVNNNINSVDNNINNVDNNINSVN 
32 MAL13P1.147 NIIQIKNDIEQCQKSIKKIEDNLNTYE 
33 PF13_0277 YIDDVDRDVENYDKGIANVDHHLNDVH 
34 MAL13P1.336 NMNNMNNNMNNMNNNMNNNMNNMNNMN 
35 PF14_0045 ARDDIQKDINKMESELINVSNEINRLD 
36 PF14_0093 SSNNLSDQINILNNNIQHINSTFNNLR 
37 PF14_0175 NNNVNNINMNNINSNVNNINNSMNNIN 
38 PF14_0089 NITNINKNIENIKNDMSNLNNMNDSNQ 
39 PF11_0210 IEINMLTNNLLREMMKIKNKLQKLSNLLNALRSNIEKILKN 
40 PFC0235w NEIKELNNTLNKYKEEMNNYKEEIIVINEKYKLLEIELCK 
41 PF11_0455 RLINNIEEIYNSNCEQIQNVRDEFAELKNDLNKIMNLINI 
42 PF07_0014 NSLDYYKKVIIKLKNNINNMEEYTNNITNDINVLKAHID 
43 PFD0685c STDINSLNDEVKKLKEELNKIRNEYDDFKNKLELLYQK 
44 MAL6P1.61 IPLNQKVLEISKKLNNMNNNINEYKNYLSNFIHMLKE 
45 PF11_0207 EEIKEEIKEVKEEIKEVKEEIKEVKEEIKEVKEEIKE 
46 MAL13P1.176 TIVQNSYNSFSDINKNINDIDKEMKTLIPMLDELLNE 
47 PFA0635c NHDTRINDYNKRLTEYNKRLTEYNKRLTEYTKRLNE 
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48 PF11_0240 KGLEEANEKLQIVREKVQSLKAKLSELISQYDHAIY 
49 MAL6P1.80 NNINNINNNINNINNNINNINNNINNINNNVNNYY 
50 PFL1605w KNDINVQLDDINVQLDDINVQLDDINIQLDEINLN 
51 PFD0985w DNNVNNMDNNVNNVDNNVNNVDNNLNNVDNNVNN 
52 PFL0770w KIQIEEIKKETNQINKDIDHIEMNIINLKKKIEF 
53 PFE0595w MSQEKISEIIKDISALKTSCEKLNSQLDELITQ 
54 MAL6P1.147 DSMNNHKDDMNNYNDNINNYVESMNNYDDIMNK 
55 PF13_0065 TSFSKYVRQLEQYFDNFDQDFLSLRQKISDILQ 
56 PF14_0013 PYLRRAKHNLNNLQGGINNLYSSVNVVYDNLFN 
57 PF13_0198 MEIKTIVQNSYNSFSDINKNINDIDKEMKTLI 
58 TISELEQEFNNNNQKLDNILQDINAMNLNINILQT 
59 PF14_0397 SLLDTLEKSVKGIDENIEKYNKELNVIKQKIE 
60 PFC0810c KNVIELKEYLEDLKKRMFDMQKRLNDIIITK 
61 MAL7P1.13 SNKTFEKLNEKLNDIRNDVTNYKNELEEFKN 
62 PFL0150w SSISSSLTNISSSLTNISSSLTNISSSLSNS 
63 PF14_0444 NNEMDETINKLKKDINKLNEKIEKYDNFMKM 
64 MAL6P1.131 NNFVNNKMNNMNNMKNNMNNMNNIMNNIMN 
65 PFB0460c NNVIRSKMYNIKKRISKINDELHELSNFFL 
66 PFL0250w MCELNVMENNMNNIHSNNNNISTHMDDVIE 
67 PFL1235c TYTLSKLNNQINELTKKINILRGNLDKARK 
68 PFL2310w NFFLEQMENDMSSTYDKMNRINMDLSKLKR 
69 PF13_0088 EKLVKHLDVIDKLIENIYDNINNLNEYINK 
70 PFB0765w EKLNDMQKKLNDVNEKYKNIVECLNNYKT 
71 KLEEMKQKNKELINNLNDISDELKNCIEQVNSVSRNMANVEK 
72 PFC0760c EEIYKLNNDIDMLSNNCKKLKESIMMMEK 
73 KEIQMLKNQILSLEESIKSLNEFINNLKN 
74 PFE0100w TLIDSFNLNLSYLRESINNKKKHINKIND 
75 PFL2520w EKLYILEKSINKLKKLLNDINNKYQTIKK 
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76 MAL13P1.304 GGLKNSNHNLNNIEMKYNTLNNNMNSINK 
77 PF08_0048 EKLKKYNNEISSLKKELDILNEKMGKCT 
78 PF07_0021 KNMDTVYKNIINMSNNMTQMYNSMNNMSHNIINASHDMMDASGNINSH 
79 PFB0315w EKMNMKMEQMDMKMEKIDVNMDQMDVKMEQMDVKMEQMDVKMKR
MNK 
80 MAL8P1.12 KNKLNKKWEQINDHINNLETNINDYNKKIKEGDSQLNNIQLQCENIEQKIN
KIKE 
81 PF07_0086 NEMNKEVNKMNEEVNKMNEEVNKMNEEVNKMNKEVNKMDEEVNKMN
KEVNKMNK 
82 MAL13P1.96 EIINEIEKKIEDIEKNINITKENLKELENKITELQSSFSSYENEMKHVVKKIE
DLEK 
83 PFC0345w QNKMENDMNIIKNDMNIMENDMNIMENDMNIIKNDMNIMEKDMNIIKND
MNIIKNNMNIIKNEMNIIKNV 
84 PFL0115w DFLDVIYYKLNIKEINKSLTEVKNELTELQKNQEEAKNILAFK 
85 PFL0350c ASIDNINKNINCINNDVDNINSNINNINDNIHKINSNVYGN 
86 PFL1930w NFIKELELQIKNLNNEINTLNDMLKDSEEEIRMLNHTLEEK 
87 KYKIEINVLNDEITKLKNEINTYKNDLKNINATLDFYKST 
88 PF13_0120 NVLEYAELIIDRQRDKINELEKKLEELRSSSEELQKNVIK 
89 PF13_0239 GIFIYNMNLLREILKLMTDNIDTLKDKINEIKCSYAFLK 
90 PFD0520c TKKLNKELSEGNKELEKLEKNIKELEETNNTLENDIKV 
91 PF07_0111 NFVNNYINENILNLKSVDNYLEKINNKIKDLDDNINDR 
92 MAL6P1.254 PDFDAYNEKLGSISQSIDEIKKKIDNLQKEIKVANK 
93 PF11_0424 QLEEKTKQYNDLQNNMKTIKEQNEHLKNKFQSMGK 
94 PFD0970c ENINNMDEKINNVDEQNNNMDEKINNVDEKK 
95 PF14_0574 EKGLKSLNEKIKNYDSIIEEQKNQLENLKM 
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